https://www.avancebio.com/molecular-diagnostic-instruments-with-combined-functions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/statistical-information-from-the-june-1999-draft-guidance-and-statistical-information-for-in-vitro-bioequivalence-data-posted-on-august-18-1999/ 2026-08-05T18:59:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/epidermolysis-bullosa-developing-drugs-for-treatment-of-cutaneous-manifestations-guidance-for-industry/ 2026-08-05T18:59:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s1cr2-dose-selection-for-carcinogenicity-studies-of-pharmaceuticals/ 2026-08-05T18:59:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/responding-to-fda-form-483-observations-at-the-conclusion-of-a-drug-cgmp-inspection/ 2026-08-05T18:59:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-gases-current-good-manufacturing-practice-draft-guidance-for-industry/ 2026-08-05T18:59:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-international-conference-on-harmonisation-regions/ 2026-08-05T18:59:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-submission-template-for-medical-device-de-novo-requests-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/procedures-for-renewal-and-amendment-of-certain-laser-light-show-variances-laser-notice-55/ 2026-08-05T18:59:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/women-and-minorities-guidance-requirements/ 2026-08-05T18:59:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bioanalytical-method-validation-for-biomarkers/ 2026-08-05T18:59:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/applicability-of-the-performance-standard-for-high-intensity-mercury-vapor-discharge-lamps-21-cfr-1040-30/ 2026-08-05T18:59:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/conducting-clinical-trials-with-decentralized-elements/ 2026-08-05T18:59:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/regulatory-considerations-for-microneedling-products-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/noise-claims-in-hearing-aid-labeling-guidance-for-industry/ 2026-08-05T18:59:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/self-selection-studies-for-nonprescription-drug-products/ 2026-08-05T18:59:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluation-of-thermal-effects-of-medical-devices-that-produce-tissue-heating-and-or-cooling-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/enforcement-policy-regarding-investigational-new-drug-requirements-for-use-of-fecal-microbiota-for-transplantation-to-treat-clostridium-difficile-infection-not-responsive-to-standard-therapies-guidan/ 2026-08-05T18:59:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q8r2-pharmaceutical-development/ 2026-08-05T18:59:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/low-sexual-interest-desire-and-or-arousal-in-women-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T18:59:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m3r2nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-authorization-for-pharmaceuticals-questions-and-answers/ 2026-08-05T18:59:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-nonclinical-datasets-for-evaluation-of-rodent-carcinogenicity-studies-of-pharmaceuticals/ 2026-08-05T18:59:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommended-statement-for-over-the-counter-aspirin-containing-drug-products-labeled-with-cardiovascular-related-imagery-guidance-for-industry/ 2026-08-05T18:59:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/in-vitro-diagnostic-ivd-device-studies-frequently-asked-questions-guidance-for-industry-and-fda-staff/ 2026-08-05T18:59:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/surveying-leveling-and-alignment-laser-products-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-215-target-animal-safety-effectiveness-protocol-development-submission/ 2026-08-05T18:59:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments/ 2026-08-05T18:59:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/how-to-comply-with-the-pediatric-research-equity-act/ 2026-08-05T18:59:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e2bm-data-elements-for-transmission-of-individual-case-safety-reports/ 2026-08-05T18:59:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/charging-for-investigational-drugs-under-an-ind-questions-and-answers/ 2026-08-05T18:59:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/testing-for-biotin-interference-in-in-vitro-diagnostic-devices-guidance-for-industry/ 2026-08-05T18:59:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/determining-the-extent-of-safety-data-collection-needed-in-late-stage-premarket-and-postapproval-clinical-investigations/ 2026-08-05T18:59:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-long-term-clinical-neurodevelopmental-safety-studies-in-neonatal-product-development-guidance-for-industry/ 2026-08-05T18:59:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/integrated-summary-of-effectiveness/ 2026-08-05T18:59:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/keratome-and-replacement-keratome-blades-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/ 2026-08-05T18:59:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/verification-systems-under-the-drug-supply-chain-security-act-for-certain-prescription-drugs-guidance-for-industry/ 2026-08-05T18:59:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/media-fills-for-validation-of-aseptic-preparations-for-positron-emission-tomography/ 2026-08-05T18:59:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/photobiomodulation-pbm-devices-premarket-notification-510k-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/identification-of-manufacturing-establishments-in-applications-submitted-to-cber-and-cder-questions-and-answers/ 2026-08-05T18:59:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/expedited-programs-for-serious-conditions-drugs-and-biologics/ 2026-08-05T18:59:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/potency-assurance-for-cellular-and-gene-therapy-products/ 2026-08-05T18:59:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-152-evaluating-the-safety-of-antimicrobial-new-animal-drugs-with-regard-to-their-microbiological-effects-on-bacteria-of-human-health-concern/ 2026-08-05T18:59:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-annex-i-residue-on-ignition-sulphated-ash-general-chapter/ 2026-08-05T18:59:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/core-patient-reported-outcomes-in-cancer-clinical-trials-guidance-for-industry/ 2026-08-05T18:59:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/neglected-tropical-diseases-of-the-developing-world-developing-drugs-for-treatment-or-prevention/ 2026-08-05T18:59:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/prescription-drug-marketing-act-donation-of-prescription-drug-samples-to-free-clinics/ 2026-08-05T18:59:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fulfilling-regulatory-requirements-for-postmarketing-submissions-of-interactive-promotional-media-for-prescription-human-and-animal-drugs-and-biologics/ 2026-08-05T18:59:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-otc-human-drug-products-using-a-column-format/ 2026-08-05T18:59:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-355-200-electrical-muscle-stimulators/ 2026-08-05T18:59:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-information-incorporated-into-human-prescription-drug-and-biological-products-labeling-good-review-practice/ 2026-08-05T18:59:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-93-vich-gl11r-impurities-in-new-veterinary-medicinal-products/ 2026-08-05T18:59:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s3a-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies/ 2026-08-05T18:59:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3dr2-guideline-for-elemental-impurities-international-council-for-harmonisation-draft-guidance-for-industry/ 2026-08-05T18:59:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-dual-510k-and-clia-waiver-by-application-studies-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/factors-to-consider-regarding-benefit-risk-in-medical-device-product-availability-compliance-and-enforcement-decisions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/sunscreen-innovation-act-withdrawal-of-a-586a-request-or-pending-request-guidance-for-industry/ 2026-08-05T18:59:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-devices-containing-materials-derived-from-animal-sources-except-for-in-vitro-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postapproval-methods-to-capture-safety-and-efficacy-data-for-cell-and-gene-therapy-products-draft-guidance-for-industry/ 2026-08-05T18:59:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-for-human-prescription-drug-and-biological-products-approved-under-the-accelerated-approval-regulatory-pathway/ 2026-08-05T18:59:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-234-question-based-review-for-the-chemistry-manufacturing-and-controls-technical-section-of-animal-drug-applications/ 2026-08-05T18:59:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transfusion-transmitted-malaria-guidance-for-industry/ 2026-08-05T18:59:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/small-entity-compliance-guide-what-you-need-to-know-about-administrative-detention-of-foods/ 2026-08-05T18:59:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hospital-bed-system-dimensional-and-assessment-guidance-to-reduce-entrapment-guidance-for-industry-and-fda-staff/ 2026-08-05T18:59:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-96-vich-gl13-effectiveness-of-anthelmintics-specific-recommendations-for-ovines/ 2026-08-05T18:59:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-224-vich-gl52-bioequivalence-blood-level-bioequivalence-study/ 2026-08-05T18:59:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-dura-substitute-devices-guidance-for-industry/ 2026-08-05T18:59:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/andas-pre-submission-facility-correspondence-related-to-prioritized-generic-drug-submissions/ 2026-08-05T18:59:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/platform-technology-designation-program-for-drug-development/ 2026-08-05T18:59:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/heparin-for-drug-and-medical-device-use-monitoring-crude-heparin-for-quality-guidance-for-industry/ 2026-08-05T18:59:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/certain-postapproval-requirements-and-resources-for-andas/ 2026-08-05T18:59:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-device-classification-product-codes-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/antibacterial-therapies-for-patients-with-an-unmet-medical-need-for-the-treatment-of-serious-bacterial-diseases-questions-and-answers-guidance-for-industry/ 2026-08-05T18:59:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluation-of-gastric-ph-dependent-drug-interactions-with-acid-reducing-agents-study-design-data-analysis-and-clinical-implications-guidance-for-industry-guidance-for-industry/ 2026-08-05T18:59:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chronic-hepatitis-b-virus-infection-developing-drugs-for-treatment/ 2026-08-05T18:59:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/off-the-shelf-software-use-in-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonprescription-sunscreen-drug-products-format-and-content-of-data-submissions/ 2026-08-05T18:59:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hernia-mesh-package-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/reporting-amount-of-listed-drugs-and-biological-products-technical-conformance-guide-guidance-for-industry/ 2026-08-05T18:59:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-best-practices-for-convening-a-gras-panel/ 2026-08-05T18:59:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q12-technical-and-regulatory-considerations-for-pharmaceutical-product-lifecycle-management-guidance-for-industry-guidance-for-industry/ 2026-08-05T18:59:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/changes-to-an-approved-nda-or-anda-questions-and-answers-guidance-for-industry/ 2026-08-05T18:59:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/global-unique-device-identification-database-gudid-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-studies-of-implantable-minimally-invasive-glaucoma-surgical-migs-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/collection-of-platelets-by-automated-methods-guidance-for-industry-and-fda-review-staff/ 2026-08-05T18:59:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/transfer-of-a-premarket-notification-510k-clearance-questions-and-answers-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T18:59:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e19-a-selective-approach-to-safety-data-collection-in-specific-late-stage-pre-approval-or-post-approval-clinical-trials/ 2026-08-05T18:59:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pet-drug-applications-content-and-format-for-ndas-and-andas_2011/ 2026-08-05T18:59:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acute-radiation-syndrome-developing-drugs-for-prevention-and-treatment/ 2026-08-05T18:59:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/importation-of-certain-fda-approved-human-prescription-drugs-including-biological-products-and-combination-products-under-section-801d1b-of-the-federal-food-drug-and-cosmetic-act-guidance/ 2026-08-05T18:59:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-plasmid-dna-vaccines-for-infectious-disease-indications-guidance-for-industry/ 2026-08-05T18:59:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-for-prevention-or-treatment/ 2026-08-05T18:59:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cancer-clinical-trial-eligibility-criteria-patients-with-organ-dysfunction-or-prior-or-concurrent-malignancies/ 2026-08-05T18:59:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-490-100-process-validation-requirements-for-drug-products-and-active-pharmaceutical-ingredients-subject-to-pre-market-approval/ 2026-08-05T18:59:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/advancement-of-emerging-technology-applications-for-pharmaceutical-innovation-and-modernization-guidance-for-industry/ 2026-08-05T19:00:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-studies-for-the-safety-evaluation-of-pharmaceutical-excipients/ 2026-08-05T19:00:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/technical-performance-assessment-of-digital-pathology-whole-slide-imaging-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under-gdufa-guidance-for-industry/ 2026-08-05T19:00:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/manufacturers-sharing-patient-specific-information-from-medical-devices-with-patients-upon-request-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports/ 2026-08-05T19:00:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-315-100-illegal-interstate-commercial-shipment-of-dentures-cpg-retitled-and-revised-5-19-2005/ 2026-08-05T19:00:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m9-biopharmaceutics-classification-system-based-biowaivers/ 2026-08-05T19:00:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-submissions-in-electronic-format-postmarketing-safety-reports/ 2026-08-05T19:00:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q5b-quality-of-biotechnological-products-analysis-of-the-expression-construct-in-cells-used-for-production-of-r-dna-derived-protein-products/ 2026-08-05T19:00:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/an-acceptable-circular-of-information-for-the-use-of-human-blood-and-blood-components-guidance-for-industry/ 2026-08-05T19:00:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-trial-endpoints-for-the-approval-of-cancer-drugs-and-biologics-guidance-for-industry/ 2026-08-05T19:00:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acute-bacterial-skin-and-skin-structure-infections-developing-drugs-for-treatment/ 2026-08-05T19:00:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/andas-impurities-in-drug-substances-guidance-for-industry/ 2026-08-05T19:00:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-guidance-for-industry-food-and-drug-administration-staff-and-third-party-review-organizations/ 2026-08-05T19:00:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2022/ 2026-08-05T19:00:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-260-type-vii-veterinary-master-file-for-research-and-development-and-risk-reviews/ 2026-08-05T19:00:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e3-structure-and-content-of-clinical-study-reports-questions-and-answers-r1/ 2026-08-05T19:00:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/studying-multiple-versions-of-a-cellular-or-gene-therapy-product-in-an-early-phase-clinical-trial-guidance-for-industry/ 2026-08-05T19:00:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/patient-engagement-in-the-design-and-conduct-of-medical-device-clinical-studies-guidance-for-industry-food-and-drug-administration-staff-and-other-stakeholders/ 2026-08-05T19:00:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/mixing-diluting-or-repackaging-biological-products-outside-the-scope-of-an-approved-biologics-license-application-guidance-for-industry/ 2026-08-05T19:00:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s12-nonclinical-biodistribution-considerations-for-gene-therapy-products-guidance-for-industry/ 2026-08-05T19:00:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e6r3-good-clinical-practice-annex-2/ 2026-08-05T19:00:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cybersecurity-in-medical-devices-quality-management-system-considerations-and-content-of-premarket-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-master-files-guidance-for-industry/ 2026-08-05T19:00:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/andas-stability-testing-of-drug-substances-and-products-questions-and-answers/ 2026-08-05T19:00:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-investigations-for-prostate-tissue-ablation-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/administrative-procedures-for-clia-categorization-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-and-fda-staff-spinal-system-510ks/ 2026-08-05T19:00:14+00:00 https://www.avancebio.com/cvm-gfi-159-vich-gl36-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-general-approach-to-establish-a-microbiological-adi/ 2026-08-05T19:00:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/on-the-content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description-information-for-an-allergenic-extract-or-allergen-patch-test-guidance-for-industry/ 2026-08-05T19:00:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/updating-anda-labeling-after-the-marketing-application-for-the-reference-listed-drug-has-been-withdrawn-guidance-for-industry/ 2026-08-05T19:00:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dental-curing-lights-premarket-notification-510k-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postmarketing-studies-and-clinical-trials-determining-good-cause-for-noncompliance-with-section-505o3eii-of-the-federal-food-drug-and-cosmetic-act-draft-guidance-for-industry/ 2026-08-05T19:00:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/the-510k-program-evaluating-substantial-equivalence-in-premarket-notifications-510k-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/ 2026-08-05T19:00:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/benefit-risk-assessment-for-new-drug-and-biological-products/ 2026-08-05T19:00:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use-as-an-endpoint-to-support-accelerated-approval/ 2026-08-05T19:00:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/facility-definition-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:00:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/naming-of-drug-products-containing-salt-drug-substances/ 2026-08-05T19:00:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q2b-validation-of-analytical-procedures-methodology/ 2026-08-05T19:00:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigational-new-drug-applications-prepared-and-submitted-by-sponsor-investigators/ 2026-08-05T19:00:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transmission-of-mycobacterium-tuberculosis-mtb-by-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:00:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/migraine-developing-drugs-for-preventive-treatment/ 2026-08-05T19:00:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/aqueous-shunts-510k-submissions-guidance-for-industry-and-for-fda-reviewers-staff/ 2026-08-05T19:00:22+00:00 https://www.avancebio.com/oncology-drug-products-used-with-certain-in-vitro-diagnostic-tests-pilot-program-guidance-for-industry-clinical-laboratories-and-food-and-drug-administration-staff/ 2026-08-05T19:00:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/consumer-antiseptic-rub-final-rule-questions-and-answers-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:00:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q11-development-and-manufacture-of-drug-substances-questions-and-answers-chemical-entities-and-biotechnological-biological-entities/ 2026-08-05T19:00:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-device-user-fee-small-business-qualification-and-determination-guidance-for-industry-food-and-drug-administration-staff-and-foreign-governments/ 2026-08-05T19:00:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/rare-diseases-early-drug-development-and-the-role-of-pre-ind-meetings-draft-guidance-for-industry/ 2026-08-05T19:00:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/potassium-iodide-tablets-shelf-life-extension/ 2026-08-05T19:00:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-clinical-trial-datasets-and-documentation-for-clinical-outcome-assessments-using-item-response-theory/ 2026-08-05T19:00:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/unique-device-identifier-system-frequently-asked-questions-vol-1-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/temporary-policies-for-compounding-certain-parenteral-drug-products-guidance-for-industry/ 2026-08-05T19:00:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs/ 2026-08-05T19:00:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-the-submission-of-510ks-for-solid-state-x-ray-imaging-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/standards-for-the-prompt-review-of-efficacy-supplements-including-priority-efficacy-supplements-guidance-for-industry/ 2026-08-05T19:00:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/certain-ophthalmic-products-policy-regarding-compliance-with-21-cfr-part-4-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:00:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-determination-of-status-as-a-qualified-facility/ 2026-08-05T19:00:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/innovative-designs-for-clinical-trials-of-cellular-and-gene-therapy-products-in-small-populations-draft-guidance-for-industry/ 2026-08-05T19:00:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:00:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-gene-therapy-for-hemophilia-guidance-for-industry/ 2026-08-05T19:00:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/container-and-closure-system-integrity-testing-in-lieu-of-sterility-testing-as-a-component-of-the-stability-protocol-for-sterile-products-guidance-for-industry/ 2026-08-05T19:00:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compounding-and-repackaging-of-radiopharmaceuticals-by-state-licensed-nuclear-pharmacies-and-federal-facilities-guidance-for-industry/ 2026-08-05T19:00:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/content-of-investigational-device-exemptions-for-solutions-for-hypothermic-flushing-transport-and-storage-of-organs-for-transplantation-guidance-for-industry-and-fda-reviewers/ 2026-08-05T19:00:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigational-in-vitro-diagnostics-in-oncology-trials-streamlined-submission-process-for-study-risk-determination-guidance-for-industry/ 2026-08-05T19:00:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-in-demonstrating-interchangeability-with-a-reference-product-guidance-for-industry/ 2026-08-05T19:00:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3c-appendix-6/ 2026-08-05T19:00:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/metal-expandable-biliary-stents-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-premarket-notifications-for-lamotrigine-and-zonisamide-assays-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-on-the-department-of-defense-exemption-from-the-fda-performance-standard-for-laser-products-guidance-for-industry-and-fda/ 2026-08-05T19:00:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/competitive-generic-therapies/ 2026-08-05T19:00:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/surgical-staplers-and-staples-for-internal-use-labeling-recommendations-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-clinical-laboratory-improvement-amendments-of-1988-clia-waiver-applications-for-manufacturers-of-in-vitro-diagnostic-devices-guidance-for-industry-and-food-and-drug-administrati/ 2026-08-05T19:00:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-and-industry-actions-on-premarket-notification-510k-submissions-effect-on-fda-review-clock-and-goals-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/qualification-of-biomarker-plasma-fibrinogen-in-studies-examining-exacerbations-and-or-all-cause-mortality-in-patients-with-chronic-obstructive-pulmonary-disease-guidance-for-industry/ 2026-08-05T19:00:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/andas-stability-testing-of-drug-substances-and-products/ 2026-08-05T19:00:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/live-case-presentations-during-investigational-device-exemption-ide-clinical-trials-guidance-for-institutional-review-boards-industry-clinical-investigators-and-food-and-drug-administration-staf/ 2026-08-05T19:00:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/requalification-of-donors-previously-deferred-for-a-history-of-viral-hepatitis-after-the-11th-birthday-guidance-for-industry/ 2026-08-05T19:00:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/anda-submissions-refuse-to-receive-for-lack-of-justification-of-impurity-limits-guidance-for-industry/ 2026-08-05T19:00:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/carcinogenicity-study-protocol-submissions/ 2026-08-05T19:00:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/container-closure-systems-for-packaging-human-drugs-and-biologics-questions-and-answers-guidance-for-industry/ 2026-08-05T19:00:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/smallpox-variola-virus-infection-developing-drugs-for-treatment-or-prevention-guidance-for-industry/ 2026-08-05T19:00:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/determining-whether-to-submit-an-anda-or-a-505b2-application/ 2026-08-05T19:00:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/slowly-progressive-low-prevalence-rare-diseases-with-substrate-deposition-that-results-from-single-enzyme-defects-providing-evidence-of-effectiveness-for-replacement-or-corrective-therapies-guidance/ 2026-08-05T19:00:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers/ 2026-08-05T19:00:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/non-clinical-and-clinical-investigation-of-devices-used-for-the-treatment-of-benign-prostatic-hyperplasia-bph-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigational-new-drug-applications-for-positron-emission-tomography-pet-drugs/ 2026-08-05T19:00:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3ar-impurities-in-new-drug-substances/ 2026-08-05T19:00:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/classification-and-requirements-for-laser-illuminated-projectors-lips-laser-notice-no-57-guidance-for-industry-and-food-and-drug-administration/ 2026-08-05T19:00:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/migraine-developing-drugs-for-acute-treatment/ 2026-08-05T19:00:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m4er2-the-ctd-efficacy/ 2026-08-05T19:00:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/rare-diseases-considerations-for-the-development-of-drugs-and-biological-products/ 2026-08-05T19:00:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessment-of-radiofrequency-induced-heating-in-the-magnetic-resonance-mr-environment-for-multi-configuration-passive-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-nonprescription-sunglasses-guidance-for-industry/ 2026-08-05T19:00:43+00:00 https://www.avancebio.com/submitting-clinical-trial-datasets-to-evaluate-the-impact-of-immunogenicity-on-the-pharmacokinetics-of-a-drug/ 2026-08-05T19:00:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/levothyroxine-sodium-products-enforcement-of-august-14-2001-compliance-date-and-submission-of-new-applications/ 2026-08-05T19:00:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-214-vich-gl35-pharmacovigilance-of-veterinary-medicinal-products-electronic-standards-for-transfer-of-data/ 2026-08-05T19:00:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/saline-silicone-gel-and-alternative-breast-implants-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e4-dose-response-information-to-support-drug-registration/ 2026-08-05T19:00:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-335-700-surgeons-gloves-and-patient-examination-gloves-defects-criteria-for-direct-reference-seizure/ 2026-08-05T19:00:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluating-the-risks-of-drug-exposure-in-human-pregnancies/ 2026-08-05T19:00:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/validation-of-procedures-for-processing-of-human-tissues-intended-for-transplantation-guidance-for-industry/ 2026-08-05T19:00:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-the-use-of-artificial-intelligence-to-support-regulatory-decision-making-for-drug-and-biological-products-draft-guidance-for-industry-and-other-interested-parties/ 2026-08-05T19:00:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/leveraging-existing-clinical-data-for-extrapolation-to-pediatric-uses-of-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pat-a-framework-for-innovative-pharmaceutical-development-manufacturing-and-quality-assurance-guidance-for-industry/ 2026-08-05T19:00:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/new-clinical-investigation-exclusivity-3-year-exclusivity-for-drug-products-questions-and-answers/ 2026-08-05T19:00:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/remote-interactive-evaluations-of-drug-manufacturing-and-bioresearch-monitoring-facilities/ 2026-08-05T19:00:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-source-data-in-clinical-investigations-guidance-for-industry/ 2026-08-05T19:00:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/multiple-endpoints-in-clinical-trials-guidance-for-industry/ 2026-08-05T19:00:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q1b-photostability-testing-of-new-drug-substances-and-products/ 2026-08-05T19:00:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies/ 2026-08-05T19:00:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development-of-pharmaceuticals-guidance-for-industry/ 2026-08-05T19:00:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-400-100-drugs-human-failure-to-register/ 2026-08-05T19:00:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/radio-frequency-wireless-technology-in-medical-devices-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/reviewers-guidance-checklist-for-orthopedic-external-fixation-devices-version-5/ 2026-08-05T19:00:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/type-2-diabetes-mellitus-evaluating-the-safety-of-new-drugs-for-improving-glycemic-control-guidance-for-industry/ 2026-08-05T19:00:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-device-accessories-describing-accessories-and-classification-pathways-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/potency-tests-for-cellular-and-gene-therapy-products-final-guidance-for-industry/ 2026-08-05T19:00:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/alcoholism-developing-drugs-for-treatment/ 2026-08-05T19:00:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/ind-submissions-for-individualized-antisense-oligonucleotide-drug-products-for-severely-debilitating-or-life-threatening-diseases-clinical-recommendations-draft-guidance-for-industry/ 2026-08-05T19:00:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-study-designs-for-catheter-ablation-devices-for-treatment-of-atrial-flutter-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-considerations-for-container-labels-and-carton-labeling-design-to-minimize-medication-errors/ 2026-08-05T19:00:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/procedures-for-meetings-of-the-medical-devices-advisory-committee-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:00:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pharmacogenetic-tests-and-genetic-tests-for-heritable-markers-guidance-for-industry-and-fda-staff/ 2026-08-05T19:00:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/real-world-data-assessing-registries-to-support-regulatory-decision-making-for-drug-and-biological-products/ 2026-08-05T19:01:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-in-or-on-medicated-feed-or-drinking-water-of-food-producing-animals-recommendations-for-drug-sponsors-for-voluntari/ 2026-08-05T19:01:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/changes-to-disposable-manufacturing-materials-questions-and-answers-guidance-for-industry/ 2026-08-05T19:01:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bridging-for-drug-device-and-biologic-device-combination-products-draft-guidance-for-industry/ 2026-08-05T19:01:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/uniform-contraceptive-labeling-guidance-for-industry/ 2026-08-05T19:01:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dental-cements-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/prescription-drug-user-fee-act-waivers-for-fixed-combination-antiretroviral-drugs-for-the-presidents-emergency-plan-for-aids-relief-draft-guidance-for-industry/ 2026-08-05T19:01:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-refusal-of-inspection-by-a-foreign-food-establishment-or-foreign-government/ 2026-08-05T19:01:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-256-compounding-animal-drugs-from-bulk-drug-substances/ 2026-08-05T19:01:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/orally-inhaled-and-intranasal-corticosteroids-evaluation-of-the-effects-on-growth-in-children/ 2026-08-05T19:01:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-user-fees-under-the-generic-drug-user-fee-amendments-of-2022/ 2026-08-05T19:01:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling-enforcement-policy/ 2026-08-05T19:01:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m12-drug-interaction-studies-questions-and-answers/ 2026-08-05T19:01:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/insanitary-conditions-at-compounding-facilities-guidance-for-industry/ 2026-08-05T19:01:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/spl-standard-for-content-of-labeling-technical-qs-as/ 2026-08-05T19:01:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-notification-requirements-concerning-gowns-intended-for-use-in-health-care-settings-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/endotoxin-testing-recommendations-for-single-use-intraocular-ophthalmic-devices/ 2026-08-05T19:01:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/orthopedic-fracture-fixation-plates-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-electronic-format-standardized-study-data/ 2026-08-05T19:01:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bioanalytical-method-validation-guidance-for-industry/ 2026-08-05T19:01:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/food-effect-bioavailability-and-fed-bioequivalence-studies-guidance-for-industry/ 2026-08-05T19:01:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-approval-application-and-humanitarian-device-exemption-modular-review-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/implanted-blood-access-devices-for-hemodialysis-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-or-detection-and-differentiation-of-influenza-viruses-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:10+00:00 https://www.avancebio.com/accelerated-approval-expedited-program-for-serious-conditions/ 2026-08-05T19:01:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigating-and-reporting-adverse-reactions-related-to-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-regulated-solely-under-section-361-of-the-public-health-service-act-and-2/ 2026-08-05T19:01:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-in-animal-foods/ 2026-08-05T19:01:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-to-the-center-for-biologics-evaluation-and-research-cber-in-electronic-format-biologics-marketing-applications-guidance-for-industry/ 2026-08-05T19:01:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-exports-under-the-fda-export-reform-and-enhancement-act-of-1996-guidance-for-industry/ 2026-08-05T19:01:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compliance-policy-regarding-premarket-and-other-requirements-for-certain-niosh-approved-air-purifying-respirators-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-for-over-the-counter-human-use-small-entity-compliance-guide/ 2026-08-05T19:01:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-notification-510k-submissions-for-testing-for-skin-sensitization-to-chemicals-in-natural-rubber-products-guidance-for-industry-and-fda-reviewers-staff/ 2026-08-05T19:01:13+00:00 https://www.avancebio.com/evidentiary-expectations-for-510k-implant-devices-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-recovered-from-donors-who-were-tested-for-communicable-diseases-using-pooled-specimens-or-diagnostic-tests-guidance-for-i/ 2026-08-05T19:01:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3c-appendix-5/ 2026-08-05T19:01:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-653-100-animal-grooming-aids/ 2026-08-05T19:01:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-156-comparability-protocols-chemistry-manufacturing-and-controls-information-for-new-animal-drugs/ 2026-08-05T19:01:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-and-submission-of-near-infrared-analytical-procedures/ 2026-08-05T19:01:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-79-dispute-resolution-procedures-for-science-based-decisions-on-products-regulated-by-cvm/ 2026-08-05T19:01:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/information-requests-and-discipline-review-letters-under-the-generic-drug-user-fee-amendments-guidance-for-industry/ 2026-08-05T19:01:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-serological-tests-to-reduce-the-risk-of-transmission-of-trypanosoma-cruzi-infection-in-blood-and-blood-components-guidance-for-industry/ 2026-08-05T19:01:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-evaluation-of-late-radiation-toxicity-of-therapeutic-radiopharmaceuticals/ 2026-08-05T19:01:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/osteoarthritis-structural-endpoints-for-the-development-of-drugs/ 2026-08-05T19:01:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/questions-and-answers-about-emdr-electronic-medical-device-reporting-guidance-for-industry-user-facilities-and-fda-staff/ 2026-08-05T19:01:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e2f-development-safety-update-report/ 2026-08-05T19:01:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pharmacokinetic-based-criteria-for-supporting-alternative-dosing-regimens-of-programmed-cell-death-receptor-1-pd-1-or-programmed-cell-death-ligand-1-pd-l1-blocking-antibodies-for-treatment-of-pati/ 2026-08-05T19:01:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/patient-counseling-information-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/ 2026-08-05T19:01:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-systems-electronic-records-and-electronic-signatures-in-clinical-investigations-questions-and-answers/ 2026-08-05T19:01:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance-for-industry/ 2026-08-05T19:01:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-113-vich-gl20-effectiveness-of-anthelmintics-specific-recommendations-for-felines/ 2026-08-05T19:01:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/questions-and-answers-on-quality-related-controlled-correspondence-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:01:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/repackaging-of-certain-human-drug-products-by-pharmacies-and-outsourcing-facilities-guidance-for-industry/ 2026-08-05T19:01:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/environmental-assessment-questions-and-answers-regarding-drugs-with-estrogenic-androgenic-or-thyroid-activity/ 2026-08-05T19:01:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-documents-using-real-world-data-and-real-world-evidence-to-fda-for-drug-and-biological-products/ 2026-08-05T19:01:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/topical-acne-drug-products-for-over-the-counter-human-use-revision-of-labeling-and-classification-of-benzoyl-peroxide-as-safe-and-effective-guidance-for-industry/ 2026-08-05T19:01:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-determining-eligibility-of-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:01:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-electronic-format-certain-human-pharmaceutical-product-applications-and-related-submissions-using-the-ectd-specifications-guidance-for-industry/ 2026-08-05T19:01:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-266-use-of-real-world-data-and-real-world-evidence-to-support-effectiveness-of-new-animal-drugs/ 2026-08-05T19:01:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-666-100-alternate-feeding-of-different-medicated-feeds/ 2026-08-05T19:01:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/immunogenicity-information-in-human-prescription-therapeutic-protein-and-select-drug-product-labeling-content-and-format-draft-guidance-for-industry/ 2026-08-05T19:01:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-notification-submissions-for-transfer-sets-excluding-sterile-connecting-devices-guidance-for-fda-reviewers/ 2026-08-05T19:01:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-67-small-entities-compliance-guide-for-renderers/ 2026-08-05T19:01:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/diabetes-mellitus-efficacy-endpoints-for-clinical-trials-investigating-antidiabetic-drugs-and-biological-products/ 2026-08-05T19:01:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-nucleic-acid-tests-on-pooled-and-individual-samples-from-donors-of-whole-blood-and-blood-components-including-source-plasma-and-source-leukocytes-to-adequately-and-appropriately-reduce-the-ri/ 2026-08-05T19:01:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/container-closure-systems-for-packaging-human-drugs-and-biologics-guidance-for-industry/ 2026-08-05T19:01:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e1a-the-extent-of-population-exposure-to-assess-clinical-safety-for-drugs-intended-for-long-term-treatment-of-non-life-threatening-conditions/ 2026-08-05T19:01:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-evaluating-donor-eligibility-using-individual-risk-based-questions-to-reduce-the-risk-of-human-immunodeficiency-virus-transmission-by-blood-and-blood-products-guidance-for-industr/ 2026-08-05T19:01:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fees-and-refunds-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/section-503a-bulks-list-final-rule-questions-and-answers-small-entity-compliance-guide-guidance-for-industry/ 2026-08-05T19:01:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dental-ceramics-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/failure-to-respond-to-an-anda-complete-response-letter-within-the-regulatory-timeframe-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:01:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compounding-and-repackaging-of-radiopharmaceuticals-by-outsourcing-facilities-guidance-for-industry/ 2026-08-05T19:01:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing/ 2026-08-05T19:01:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premenopausal-women-with-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:01:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/benefit-risk-factors-to-consider-when-determining-substantial-equivalence-in-premarket-notifications-510k-with-different-technological-characteristics-guidance-for-industry-and-food-and-drug-admi/ 2026-08-05T19:01:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fees-for-513g-requests-for-information-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-for-medical-devices-in-electronic-format-submissions-under-section-745ab-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-admin/ 2026-08-05T19:01:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals/ 2026-08-05T19:01:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-powered-suction-pump-510ks-guidance-for-industry-and-fda-reviewers-staff/ 2026-08-05T19:01:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/early-lyme-disease-as-manifested-by-erythema-migrans-developing-drugs-for-treatment/ 2026-08-05T19:01:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting/ 2026-08-05T19:01:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2017-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:01:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/2016-medical-gas-container-closure-rule-questions-and-answers-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:01:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/changes-or-modifications-during-the-conduct-of-a-clinical-investigation-final-guidance-for-industry-and-cdrh-staff/ 2026-08-05T19:01:40+00:00 https://www.avancebio.com/e2dr1-post-approval-safety-data-definitions-and-standards-for-management-and-reporting-of-individual-case-safety-reports/ 2026-08-05T19:01:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nucleic-acid-testing-to-reduce-the-possible-risk-of-parvovirus-b19-transmission-by-plasma-derived-products-guidance-for-industry/ 2026-08-05T19:01:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clostridioides-difficile-infection-developing-drugs-for-treatment-reduction-of-recurrence-and-prevention/ 2026-08-05T19:01:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fees-and-refunds-for-premarket-approval-applications-and-device-biologics-license-applications-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/addition-of-urls-to-electronic-product-labeling-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-bsufa-products-guidance-for-industry/ 2026-08-05T19:01:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-drug-interaction-assessment-for-therapeutic-proteins-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:01:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/information-request-and-discipline-review-letters-under-the-prescription-drug-user-fee-act-guidance-for-industry/ 2026-08-05T19:01:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs/ 2026-08-05T19:01:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/analytical-procedures-and-methods-validation-for-drugs-and-biologics/ 2026-08-05T19:01:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/surgical-masks-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/unique-device-identification-policy-regarding-compliance-dates-for-class-i-and-unclassified-devices-direct-marking-and-global-unique-device-identification-database-requirements-for-certain-devices/ 2026-08-05T19:01:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/coronary-and-carotid-embolic-protection-devices-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/intravascular-administration-sets-premarket-notification-submissions-510k-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/appeal-options-available-to-mammography-facilities-concerning-adverse-accreditation-decisions-suspension-revocation-of-certificates-or-patient-and-referring-provider-notification-orders-guidance-fo/ 2026-08-05T19:01:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/ 2026-08-05T19:01:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/draft-guidance-for-industry-application-of-the-solely-engaged-exemptions-in-parts-117-and-507/ 2026-08-05T19:01:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/technical-performance-assessment-of-quantitative-imaging-in-radiological-device-premarket-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/radioactive-drug-research-committee-human-research-without-an-investigational-new-drug-application/ 2026-08-05T19:01:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-premarket-submissions-of-orthokeratology-rigid-gas-permeable-contact-lenses-guidance-for-industry/ 2026-08-05T19:01:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-264-standardized-medicated-feed-assay-limits/ 2026-08-05T19:01:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-hiv-infection-drug-development-for-treatment/ 2026-08-05T19:01:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-devices-and-clinical-trial-design-for-the-treatment-or-improvement-in-the-appearance-of-fungally-infected-nails-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/general-considerations-for-the-use-of-new-approach-methodologies-in-drug-development/ 2026-08-05T19:01:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/symptomatic-nonerosive-gastroesophageal-reflux-disease-developing-drugs-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:01:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3c-tables-and-list-rev-4/ 2026-08-05T19:01:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3e-guideline-for-extractables-and-leachables/ 2026-08-05T19:01:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/regulatory-considerations-for-prescription-drug-use-related-software/ 2026-08-05T19:01:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chemistry-manufacturing-and-control-cmc-information-for-human-gene-therapy-investigational-new-drug-applications-inds-guidance-for-industry/ 2026-08-05T19:01:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-for-ind-and-bioavailability-bioequivalence-studies-guidance-for-industry/ 2026-08-05T19:01:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q8-q9-q10-questions-and-answers-appendix-qas-from-training-sessions-q8-q9-q10-points-to-consider/ 2026-08-05T19:01:55+00:00 https://www.avancebio.com/submission-of-abbreviated-reports-and-synopses-in-support-of-marketing-applications/ 2026-08-05T19:01:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-x-ray-imaging-devices-conformance-with-iec-standards-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:01:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/real-world-data-assessing-electronic-health-records-and-medical-claims-data-to-support-regulatory-decision-making-for-drug-and-biological-products-guidance-for-industry/ 2026-08-05T19:01:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/performance-standard-for-diagnostic-x-ray-systems-and-their-major-components-21cfr-1020-30-1020-31-1020-32-1020-33-small-entity-compliance-guide/ 2026-08-05T19:01:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-induced-liver-injury-premarketing-clinical-evaluation/ 2026-08-05T19:01:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m13b-bioequivalence-for-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver-draft-guidance-for-industry/ 2026-08-05T19:01:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-devices-with-sharps-injury-prevention-features-guidance-for-industry-and-fda-staff/ 2026-08-05T19:01:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-labeling-for-devices-that-contain-natural-rubber-21-cfr-801-437-small-entity-compliance-guide-guidance-for-industry/ 2026-08-05T19:01:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/covid-19-developing-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry/ 2026-08-05T19:02:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-user-fees-under-the-biosimilar-user-fee-amendments-of-2022-guidance-for-industry/ 2026-08-05T19:02:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/collection-of-race-and-ethnicity-data-in-clinical-trials-and-clinical-studies-for-fda-regulated-medical-products/ 2026-08-05T19:02:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nontuberculous-mycobacterial-pulmonary-disease-caused-by-mycobacterium-avium-complex-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:02:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-345-100-condoms-defects-criteria-for-direct-reference-seizure/ 2026-08-05T19:02:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/treatment-for-heart-failure-endpoints-for-drug-development-guidance-for-industry/ 2026-08-05T19:02:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/radiation-safety-considerations-for-x-ray-equipment-designed-for-hand-held-use/ 2026-08-05T19:02:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-considerations-for-studies-of-devices-intended-to-treat-opioid-use-disorder-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-229-evaluating-the-effectiveness-of-new-animal-drugs-for-the-reduction-of-pathogenic-shiga-toxin-producing-e-coli-in-cattle/ 2026-08-05T19:02:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/abuse-deterrent-opioids-evaluation-and-labeling/ 2026-08-05T19:02:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/enhanced-drug-distribution-security-requirements-under-section-582g1-of-the-federal-food-drug-and-cosmetic-act-compliance-policies/ 2026-08-05T19:02:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/revised-procedures-for-adding-lens-finishing-laboratories-to-approved-premarket-approval-applications-for-class-iii-rigid-gas-permeable-contact-lenses-for-extended-wear-guidance-for-industry-and-fda/ 2026-08-05T19:02:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m13a-bioequivalence-for-immediate-release-solid-oral-dosage-forms/ 2026-08-05T19:02:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-pharmacology-considerations-for-peptide-drug-products/ 2026-08-05T19:02:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bone-anchors-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-suicidal-ideation-and-behavior-prospective-assessment-of-occurrence-in-clinical-trials/ 2026-08-05T19:02:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-64-vich-gl2-validation-of-analytical-procedures-methodology/ 2026-08-05T19:02:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-208-vich-gl49-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-validation-of-analytical-methods-used-in-residue-depletion-studies/ 2026-08-05T19:02:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/communications-from-firms-to-health-care-providers-regarding-scientific-information-on-unapproved-uses-of-approved-cleared-medical-products-questions-and-answers/ 2026-08-05T19:02:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/manufacturing-changes-and-comparability-for-human-cellular-and-gene-therapy-products/ 2026-08-05T19:02:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-3-general-principles-for-evaluating-the-human-food-safety-of-new-animal-drugs-used-in-food-producing-animals/ 2026-08-05T19:02:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/orally-disintegrating-tablets-guidance-for-industry/ 2026-08-05T19:02:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-patient-reported-outcome-data-in-cancer-clinical-trials/ 2026-08-05T19:02:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-reporting-requirements-for-inds-and-ba-be-studies-guidance-for-industry-and-investigators/ 2026-08-05T19:02:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-guidance-document-concerning-use-of-pilot-manufacturing-facilities-for-the-development-and-manufacture-of-biological-products/ 2026-08-05T19:02:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-the-design-of-early-phase-clinical-trials-of-cellular-and-gene-therapy-products-guidance-for-industry/ 2026-08-05T19:02:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pharmacogenomic-data-submissions-companion-guidance/ 2026-08-05T19:02:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hiv-1-resistance-data-attachment-to-the-guidance-draft-draft-guidance-this/ 2026-08-05T19:02:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pdufa-pilot-project-proprietary-name-review-concept-paper/ 2026-08-05T19:02:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e15-pharmacogenomics-definitions-and-sample-coding/ 2026-08-05T19:02:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/de-novo-classification-process-evaluation-of-automatic-class-iii-designation-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluating-drug-effects-on-the-ability-to-operate-a-motor-vehicle/ 2026-08-05T19:02:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-173-animal-drug-sponsor-fees-under-the-animal-drug-user-fee-act-adufa/ 2026-08-05T19:02:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-for-over-the-counter-human-use-guidance-for-industry/ 2026-08-05T19:02:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessment-of-ovarian-toxicity-in-premenopausal-adults-during-drug-development-for-oncologic-products/ 2026-08-05T19:02:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/manufacturing-considerations-for-licensed-and-investigational-cellular-and-gene-therapy-products-during-covid-19-public-health-emergency-guidance-for-industry/ 2026-08-05T19:02:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-supply-chain-program-requirements-and-co-manufacturer-supplier-approval-and-verification-for-human-food-and-animal-food/ 2026-08-05T19:02:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-237-oncology-drugs-for-companion-animals/ 2026-08-05T19:02:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fee-waivers-reductions-and-refunds-for-drug-and-biological-products/ 2026-08-05T19:02:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-developmental-toxicity-studies-for-preventive-and-therapeutic-vaccines-for-infectious-disease-indications-guidance-for-industry/ 2026-08-05T19:02:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluating-cancer-drugs-in-patients-with-central-nervous-system-metastases-guidance-for-industry/ 2026-08-05T19:02:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nucleic-acid-testing-nat-for-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing-product-disposition-and-donor-deferral-and-reentry-guidance-for-industry/ 2026-08-05T19:02:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-97-vich-gl14-effectiveness-of-anthelmintics-specific-recommendations-for-caprines/ 2026-08-05T19:02:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-design-development-and-analytical-validation-of-next-generation-sequencing-ngs-based-in-vitro-diagnostics-ivds-intended-to-aid-in-the-diagnosis-of-suspected-germline-disease/ 2026-08-05T19:02:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-200-secg-for-designation-of-new-animal-drugs-for-minor-uses-or-minor-species/ 2026-08-05T19:02:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/approval-of-alternate-means-of-labeling-for-laser-products-laser-notice-53/ 2026-08-05T19:02:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-480-300-lack-of-expiration-date-of-stability-data/ 2026-08-05T19:02:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/post-warning-letter-meetings-under-gdufa/ 2026-08-05T19:02:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/consideration-of-uncertainty-in-making-benefit-risk-determinations-in-medical-device-premarket-approvals-de-novo-classifications-and-humanitarian-device-exemptions-guidance-for-industry-and-food-an/ 2026-08-05T19:02:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-collecting-red-blood-cells-by-automated-apheresis-methods-technical-correction-february-2001-guidance-for-industry/ 2026-08-05T19:02:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/disseminated-coccidioidomycosis-developing-drugs-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:02:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/ 2026-08-05T19:02:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/product-identifier-requirements-under-the-drug-supply-chain-security-act-compliance-policy-guidance-for-industry/ 2026-08-05T19:02:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m4-the-ctd-general-questions-and-answers/ 2026-08-05T19:02:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-guidance-for-industry-availability/ 2026-08-05T19:02:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-181-blue-bird-medicated-feed-labels/ 2026-08-05T19:02:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-69-small-entities-compliance-guide-for-feeders-of-ruminant-animals-with-on-farm-feed-mixing-operations/ 2026-08-05T19:02:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q1-stability-testing-of-drug-substances-and-drug-products-draft-guidance-for-industry/ 2026-08-05T19:02:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/formal-meetings-between-fda-and-anda-applicants-of-complex-products-under-gdufa-guidance-for-industry/ 2026-08-05T19:02:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/codevelopment-of-two-or-more-new-investigational-drugs-for-use-in-combination/ 2026-08-05T19:02:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/implementation-of-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-materials-for-use-in-screening-donors-of-blood-and-blood-components-guidance-for-industry/ 2026-08-05T19:02:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-review-of-vaccine-labeling-requirements-for-warnings-use-instructions-and-precautionary-information-guidance-for-industry/ 2026-08-05T19:02:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-118-mass-spectrometry-for-confirmation-of-identity-of-animal-drug-residues/ 2026-08-05T19:02:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-decisions-for-investigational-device-exemption-clinical-investigations-guidance-for-sponsors-clinical-investigators-institutional-review-boards-and-food-and-drug-administration-staff/ 2026-08-05T19:02:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bioavailability-and-bioequivalence-studies-submitted-in-ndas-or-inds-general-considerations/ 2026-08-05T19:02:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bioavailability-studies-submitted-in-ndas-or-inds-general-considerations/ 2026-08-05T19:02:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-74-vich-gl4-stability-testing-of-new-veterinary-dosage-forms/ 2026-08-05T19:02:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/microdose-radiopharmaceutical-diagnostic-drugs-nonclinical-study-recommendations-guidance-for-industry/ 2026-08-05T19:02:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/product-title-and-initial-u-s-approval-in-the-highlights-of-prescribing-information-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/ 2026-08-05T19:02:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/tropical-disease-priority-review-vouchers/ 2026-08-05T19:02:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/revised-recommendations-for-determining-eligibility-of-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-who-have-received-human-derived-clotting-factor-concentrates-guidance-for/ 2026-08-05T19:02:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pre-storage-leukocyte-reduction-of-whole-blood-and-blood-components-intended-for-transfusion-final-guidance-for-industry/ 2026-08-05T19:02:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/characterization-and-qualification-of-cell-substrates-and-other-biological-materials-used-in-the-production-of-viral-vaccines-for-infectious-disease-indications-guidance-for-industry/ 2026-08-05T19:02:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-labeling-changes-implementation-of-section-505o4-of-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:02:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m4-the-ctd-quality/ 2026-08-05T19:02:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/ich-q12-implementation-considerations-for-fda-regulated-products-draft-guidance-for-industry/ 2026-08-05T19:02:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s7b-nonclinical-evaluation-of-the-potential-for-delayed-ventricular-repolarization-qt-interval-prolongation-by-human-pharmaceuticals/ 2026-08-05T19:02:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pdufa-waivers-reductions-and-refunds-for-fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-under-pepfar/ 2026-08-05T19:02:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-261-eligibility-criteria-for-expanded-conditional-approval-of-new-animal-drugs/ 2026-08-05T19:02:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compliance-guide-for-cabinet-x-ray-systems/ 2026-08-05T19:02:36+00:00 https://www.avancebio.com/q5ar2-viral-safety-evaluation-of-biotechnology-products-derived-from-cell-lines-of-human-or-animal-origin/ 2026-08-05T19:02:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/ 2026-08-05T19:02:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-of-new-veterinary-drug-substances-and-medicinal-products/ 2026-08-05T19:02:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-of-non-opioid-analgesics-for-chronic-pain/ 2026-08-05T19:02:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigating-out-of-specification-oos-test-results-for-pharmaceutical-production-level-2-revision-guidance-for-industry/ 2026-08-05T19:02:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/consumer-directed-broadcast-advertisements-guidance-for-industry/ 2026-08-05T19:02:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-annex-13-bulk-density-and-tapped-density-of-powders-general-chapter/ 2026-08-05T19:02:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/patient-reported-outcome-measures-use-in-medical-product-development-to-support-labeling-claims-guidance-for-industry/ 2026-08-05T19:02:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s1br1-addendum-to-s1b-testing-for-carcinogenicity-of-pharmaceuticals-guidance-for-industry/ 2026-08-05T19:02:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q12-technical-and-regulatory-considerations-for-pharmaceutical-product-lifecycle-management-annex/ 2026-08-05T19:02:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/regulatory-considerations-for-human-cells-tissues-and-cellular-and-tissue-based-products-minimal-manipulation-and-homologous-use-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-electronic-format-ind-safety-reports-guidance-for-industry/ 2026-08-05T19:02:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/direct-to-consumer-prescription-drug-advertisements-presentation-of-the-major-statement-in-a-clear-conspicuous-and-neutral-manner-in-advertisements-in-television-and-radio-format-final-rule-questio/ 2026-08-05T19:02:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:02:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acceptable-media-for-electronic-product-user-manuals-guidance-for-industry-and-fda-staff/ 2026-08-05T19:02:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e11r1-addendum-clinical-investigation-of-medicinal-products-in-the-pediatric-population/ 2026-08-05T19:02:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/color-additive-petitions-medical-devices/ 2026-08-05T19:02:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dscsa-standards-for-the-interoperable-exchange-of-information-for-tracing-of-certain-human-finished-prescription-drugs-guidance-for-industry/ 2026-08-05T19:02:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/real-time-premarket-approval-application-pma-supplements-guidance-for-industry-and-fda-staff/ 2026-08-05T19:02:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-policy-regarding-certain-entities-subject-to-the-current-good-manufacturing-practice-and-preventive-controls-produce-safety-and-or-foreign-supplier-verification-programs/ 2026-08-05T19:02:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-and-industry-procedures-for-section-513g-requests-for-information-under-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acute-bacterial-exacerbations-of-chronic-bronchitis-in-patients-with-chronic-obstructive-pulmonary-disease-developing-antimicrobial-drugs-for-treatment/ 2026-08-05T19:02:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-the-submission-of-premarket-notifications-for-radionuclide-dose-calibrators-guidance-for-industry/ 2026-08-05T19:02:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/establishing-impurity-specifications-for-antibiotics/ 2026-08-05T19:02:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-283-priority-zoonotic-animal-drug-designation-and-review-process/ 2026-08-05T19:02:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-user-fees-under-the-over-the-counter-monograph-drug-user-fee-program/ 2026-08-05T19:02:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/developing-and-submitting-proposed-draft-guidance-relating-to-patient-experience-data/ 2026-08-05T19:02:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/the-use-of-clinical-holds-following-clinical-investigator-misconduct-guidance-for-industry-and-clinical-investigators/ 2026-08-05T19:02:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-for-pre-exposure-prophylaxis/ 2026-08-05T19:02:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-220-use-of-nanomaterials-in-food-for-animals/ 2026-08-05T19:02:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/180-day-generic-drug-exclusivity-under-the-hatch-waxman-amendments-to-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:02:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chronic-hepatitis-d-virus-infection-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:02:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-application-of-the-foreign-supplier-verification-program-regulation-to-importers-of-grain-raw-agricultural-commodities/ 2026-08-05T19:02:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-drug-development-regulatory-considerations-complying-with-the-pediatric-research-equity-act-and-qualifying-for-pediatric-exclusivity-under-the-best-pharmaceuticals-for-children-ac/ 2026-08-05T19:02:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-labeling-changes-implementation-of-section-505o4-of-the-fdc-act-draft-guidance-for-industry/ 2026-08-05T19:02:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-sterile-connecting-devices-in-blood-bank-practices-guidance-for-industry/ 2026-08-05T19:02:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pathology-peer-review-in-nonclinical-toxicology-studies-questions-and-answers/ 2026-08-05T19:02:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/blood-establishment-computer-system-validation-in-the-users-facility-guidance-for-industry/ 2026-08-05T19:02:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-for-the-treatment-or-prevention-of-human-immunodeficiency-virus-one-under-the-presidents-emergency-plan-fo/ 2026-08-05T19:02:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonmetastatic-castration-resistant-prostate-cancer-considerations-for-metastasis-free-survival-endpoint-in-clinical-trials/ 2026-08-05T19:02:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/general-principles-for-the-development-of-vaccines-to-protect-against-global-infectious-diseases-guidance-for-industry/ 2026-08-05T19:02:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/citizen-petitions-and-petitions-for-stay-of-action-subject-to-section-505q-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:02:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-determining-the-number-of-employees-for-purposes-of-the-small-business-definition-in-parts-117-and-507/ 2026-08-05T19:02:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-683-100-action-levels-for-aflatoxins-in-animal-feeds/ 2026-08-05T19:02:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/determination-of-intended-use-for-510k-devices-guidance-for-cdrh-staff-update-to-k98-1/ 2026-08-05T19:02:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support-accelerated-approval-draft-guidance-for-industry/ 2026-08-05T19:02:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/product-labeling-for-laparoscopic-power-morcellators-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-280-110-microbiological-control-requirements-licensed-anti-human-globulin-and-blood-grouping-reagents/ 2026-08-05T19:02:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/presenting-quantitative-efficacy-and-risk-information-in-direct-to-consumer-dtc-promotional-labeling-and-advertisements/ 2026-08-05T19:02:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/prohibition-on-wholesaling-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:02:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/procedures-for-handling-post-approval-studies-imposed-by-pma-order-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:02:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/information-sheet-guidance-for-sponsors-clinical-investigators-and-irbs-frequently-asked-questions-statement-of-investigator-form-fda-1572-revision-1-draft-information-sheet-guidance-for-sponso/ 2026-08-05T19:02:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/using-the-inactive-ingredient-database-guidance-for-industry/ 2026-08-05T19:02:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-necessity-of-the-use-of-food-product-categories-in-food-facility-registrations-and-updates-to-food-product-categories-2016-edition/ 2026-08-05T19:02:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-hbv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:03:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-reducing-the-risk-of-transfusion-transmitted-babesiosis-guidance-for-industry/ 2026-08-05T19:03:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/qualification-of-biomarker-total-kidney-volume-in-studies-for-treatment-of-autosomal-dominant-polycystic-kidney-disease-draft-guidance-for-industry/ 2026-08-05T19:03:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-for-industry-clinical-medical/ 2026-08-05T19:03:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cmc-postapproval-manufacturing-changes-for-specified-biological-products-to-be-documented-in-annual-reports/ 2026-08-05T19:03:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/prescription-requirement-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:03:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-for-industry/ 2026-08-05T19:03:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/revised-recommendations-regarding-invalidation-of-test-results-of-licensed-and-510k-cleared-bloodborne-pathogen-assays-used-to-test-donors-guidance-for-industry/ 2026-08-05T19:03:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/expiration-dating-and-stability-testing-of-solid-oral-dosage-form-drugs-containing-iron-guidance-for-industry/ 2026-08-05T19:03:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/standards-development-and-the-use-of-standards-in-regulatory-submissions-reviewed-in-the-center-for-biologics-evaluation-and-research-guidance-for-industry/ 2026-08-05T19:03:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-141-vich-gl28-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-carcinogenicity-testing/ 2026-08-05T19:03:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-56-protocol-development-guideline-for-clinical-effectiveness-and-target-animal-safety-trials/ 2026-08-05T19:03:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/notifying-fda-of-fatalities-related-to-blood-collection-or-transfusion-guidance-for-industry/ 2026-08-05T19:03:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/placebos-and-blinding-in-randomized-controlled-cancer-clinical-trials-for-drug-and-biological-products-guidance-for-industry/ 2026-08-05T19:03:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/format-and-content-for-the-cmc-section-of-an-annual-report/ 2026-08-05T19:03:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommended-acceptable-intake-limits-for-nitrosamine-drug-substance-related-impurities/ 2026-08-05T19:03:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3cr8-impurities-guidance-for-residual-solvents-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:03:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/draft-guidance-for-industry-questions-and-answers-regarding-the-reportable-food-registry-as-established-by-the-food-and-drug-administration-amendments-act-of-2007-edition-2/ 2026-08-05T19:03:07+00:00 https://www.avancebio.com/qtc-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-industry/ 2026-08-05T19:03:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-635-100-large-volume-parenterals-lvps-for-animal-use/ 2026-08-05T19:03:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/factors-to-consider-when-making-benefit-risk-determinations-for-medical-device-investigational-device-exemptions-guidance-for-investigational-device-exemption-sponsors-sponsor-investigators-and-food/ 2026-08-05T19:03:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-for-treatment/ 2026-08-05T19:03:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pharmacokinetics-in-patients-with-impaired-renal-function-study-design-data-analysis-and-impact-on-dosing/ 2026-08-05T19:03:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-188-data-elements-for-submission-of-veterinary-adverse-event-reports-to-the-center-for-veterinary-medicine/ 2026-08-05T19:03:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/deviation-reporting-for-human-cells-tissues-and-cellular-and-tissue-based-products-regulated-solely-under-section-361-of-the-public-health-service-act-and-21-cfr-part-1271-guidance-for-industry/ 2026-08-05T19:03:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-106-the-use-of-published-literature-in-support-of-new-animal-drug-approvals/ 2026-08-05T19:03:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/anda-submissions-content-and-format-of-abbreviated-new-drug-applications-guidance-for-industry/ 2026-08-05T19:03:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-nucleic-acid-tests-on-pooled-and-individual-samples-from-donors-of-whole-blood-and-blood-components-including-source-plasma-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-final-guid/ 2026-08-05T19:03:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/data-standards-for-drug-and-biological-product-submissions-containing-real-world-data-guidance-for-industry/ 2026-08-05T19:03:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m7r2-addendum-application-of-the-principles-of-the-ich-m7-guideline-to-calculation-of-compound-specific-acceptable-intakes-guidance-for-industry/ 2026-08-05T19:03:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-for-permanent-hysteroscopically-placed-tubal-implants-intended-for-sterilization-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-west-nile-virus-from-living-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-guidance-for-industry/ 2026-08-05T19:03:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-201-secg-for-the-index-of-legally-marketed-unapproved-new-animal-drugs-for-minor-species/ 2026-08-05T19:03:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-the-use-of-bayesian-statistics-in-medical-device-clinical-trials-pdf-version/ 2026-08-05T19:03:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-262-pre-submission-consultation-process-for-animal-food-additive-petitions-or-generally-recognized-as-safe-gras-notices/ 2026-08-05T19:03:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonproprietary-naming-of-biological-products-guidance-for-industry/ 2026-08-05T19:03:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-90-vich-gl7-effectiveness-of-anthelmintics-general-recommendations/ 2026-08-05T19:03:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-drug-development-under-the-pediatric-research-equity-act-and-the-best-pharmaceuticals-for-children-act-scientific-considerations/ 2026-08-05T19:03:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/national-uniformity-for-nonpresciption-drugs-ingredient-listing-for-otc-drugs/ 2026-08-05T19:03:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e6r3-good-clinical-practice-gcp/ 2026-08-05T19:03:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-239-human-food-by-products-for-use-as-animal-food/ 2026-08-05T19:03:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-245-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals/ 2026-08-05T19:03:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluation-of-bulk-drug-substances-nominated-for-use-in-compounding-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:03:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-annex-9-tablet-friability-general-chapter/ 2026-08-05T19:03:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral-ophthalmic-or-otic-use-guidance-for-industry/ 2026-08-05T19:03:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/product-name-placement-size-and-prominence-in-advertising-and-promotional-labeling-final/ 2026-08-05T19:03:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bioequivalence-studies-with-pharmacokinetic-endpoints-for-drugs-submitted-under-an-abbreviated-new-drug-application/ 2026-08-05T19:03:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-187a-heritable-intentional-genomic-alterations-in-animals-risk-based-approach/ 2026-08-05T19:03:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-of-antibodies-to-borrelia-burgdorferi-guidance-for-industry-and-fda-staff/ 2026-08-05T19:03:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/animal-studies-for-dental-bone-grafting-material-devices-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/magnetic-resonance-mr-receive-only-coil-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-665-300-use-of-type-a-medicated-article-proprietary-names-in-the-names-of-medicated-feeds/ 2026-08-05T19:03:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-complying-with-21-cfr-211-110/ 2026-08-05T19:03:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-and-use-of-risk-minimization-action-plans-guidance-for-industry/ 2026-08-05T19:03:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pac-atls-postapproval-changes-analytical-testing-laboratory-sites-guidance-for-industry/ 2026-08-05T19:03:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and-source-plasma-quarantine-hold-requirements-guidance-for-industry/ 2026-08-05T19:03:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:03:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/unique-device-identification-convenience-kits-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/changes-to-an-approved-nda-or-anda-specifications-use-of-enforcement-discretion-for-compendial-changes-guidance-for-industry/ 2026-08-05T19:03:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/presenting-risk-information-in-prescription-drug-and-medical-device-promotion/ 2026-08-05T19:03:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-notification-submissions-for-blood-and-plasma-warmers-guidance-for-fda-reviewers/ 2026-08-05T19:03:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/preparation-of-ides-and-inds-for-products-intended-to-repair-or-replace-knee-cartilage-guidance-for-industry/ 2026-08-05T19:03:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/frequently-asked-questions-about-the-reprocessing-and-reuse-of-single-use-devices-by-third-party-and-hospital-reprocessors-final-guidance-for-industry-and-fda-staff/ 2026-08-05T19:03:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/oral-drug-products-administered-via-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations-draft-guidance-for-industry/ 2026-08-05T19:03:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/policy-clarification-for-certain-fluoroscopic-equipment-requirements-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/design-and-analysis-of-shedding-studies-for-virus-or-bacteria-based-gene-therapy-and-oncolytic-products-guidance-for-industry/ 2026-08-05T19:03:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chemistry-manufacturing-and-controls-changes-to-an-approved-application-certain-biological-products-guidance-for-industry/ 2026-08-05T19:03:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e14-clinical-evaluation-of-qt-qtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs-questions-and-answers-r3-guidance-for-industry/ 2026-08-05T19:03:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-100-vich-gl18-r2-impurities-residual-solvents-in-new-veterinary-medicinal-products-active-substances-and-excipients-revision-2/ 2026-08-05T19:03:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/ 2026-08-05T19:03:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/eligibility-determination-for-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-guidance-for-industry/ 2026-08-05T19:03:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination-draft-guidance-for-industry/ 2026-08-05T19:03:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-products-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:03:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-gene-therapy-for-rare-diseases-guidance-for-industry/ 2026-08-05T19:03:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/translation-of-good-laboratory-practice-study-reports-questions-and-answers/ 2026-08-05T19:03:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fees-for-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-of-the-fdc-act/ 2026-08-05T19:03:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-powered-muscle-stimulator-510ks-guidance-for-industry-fda-reviewers-staff-and-compliance/ 2026-08-05T19:03:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-191-changes-to-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas/ 2026-08-05T19:03:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m10-bioanalytical-method-validation/ 2026-08-05T19:03:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-216-chemistry-manufacturing-and-controls-cmc-information-fermentation-derived-intermediates-drug-substances-and-related-drug-products-for-veterinary-medicinal-use/ 2026-08-05T19:03:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-obtaining-a-labeling-claim-for-communicable-disease-donor-screening-tests-using-cadaveric-blood-specimens-from-donors-of-human-cells-tissues-and-cellular-and-tissue-based-product/ 2026-08-05T19:03:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-electronic-format-receipt-date-guidance-for-industry/ 2026-08-05T19:03:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution-testing/ 2026-08-05T19:03:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/population-pharmacokinetics-guidance-for-industry/ 2026-08-05T19:03:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/sterility-requirement-for-aqueous-based-drug-products-for-oral-inhalation-small-entity-compliance-guide-guidance-for-industry/ 2026-08-05T19:03:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-assessment-of-donor-suitability-and-blood-and-blood-product-safety-in-cases-of-possible-exposure-to-anthrax-guidance-for-industry/ 2026-08-05T19:03:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-interaction-information-in-human-prescription-drug-and-biological-product-labeling/ 2026-08-05T19:03:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/gastroparesis-clinical-evaluation-of-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:03:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/inds-for-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information-guidance-for-industry/ 2026-08-05T19:03:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/study-of-sex-differences-in-the-clinical-evaluation-of-medical-products/ 2026-08-05T19:03:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-human-somatic-cell-therapy-and-gene-therapy-guidance-for-industry/ 2026-08-05T19:03:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/unique-device-identification-system-form-and-content-of-the-unique-device-identifier-udi-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-regulatory-framework-for-substances-intended-for-use-in-human-food-or-animal-food-on-the-basis-of-the-generally-recognized-as-safe-gras-provision-of-the-federal-food-drug-an/ 2026-08-05T19:03:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-70-small-entities-compliance-guide-for-feeders-of-ruminant-animals-without-on-farm-feed-mixing-operations/ 2026-08-05T19:03:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-lactation-studies-considerations-for-study-design/ 2026-08-05T19:03:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/heparin-containing-medical-devices-and-combination-products-recommendations-for-labeling-and-safety-testing-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-5-drug-stability-guidelines/ 2026-08-05T19:03:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-safety-evaluation-of-drug-or-biologic-combinations/ 2026-08-05T19:03:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hypertension-developing-fixed-dose-combination-drugs-for-treatment/ 2026-08-05T19:03:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chronic-rhinosinusitis-with-nasal-polyps-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:03:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:03:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/mouse-embryo-assay-for-assisted-reproduction-technology-devices/ 2026-08-05T19:03:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-226-target-animal-safety-data-presentation-and-statistical-analysis/ 2026-08-05T19:03:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s2a-specific-aspects-of-regulatory-genotoxicity-tests-for-pharmaceuticals/ 2026-08-05T19:03:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/consideration-of-enforcement-policies-for-in-vitro-diagnostic-tests-during-a-section-564-declared-emergency-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-product-tracing-the-effect-of-section-585-of-the-fdc-act/ 2026-08-05T19:03:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medication-guides-adding-a-toll-free-number-for-reporting-adverse-events/ 2026-08-05T19:03:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/gingivitis-development-and-evaluation-of-drugs-for-treatment-or-prevention/ 2026-08-05T19:03:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:03:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/the-least-burdensome-provisions-concept-and-principles-guidance-for-industry-and-fda-staff/ 2026-08-05T19:03:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-frequently-asked-questions-about-gras-for-substances-intended-for-use-in-human-or-animal-food/ 2026-08-05T19:03:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/best-practices-for-communication-between-ind-sponsors-and-fda-during-drug-development/ 2026-08-05T19:03:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pulse-oximeters-premarket-notification-submissions-510ks-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:49+00:00 https://www.avancebio.com/postmarketing-adverse-experience-reporting-for-human-drug-and-licensed-biological-products-clarification-of-what-to-report/ 2026-08-05T19:03:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pulmonary-tuberculosis-developing-drugs-for-treatment/ 2026-08-05T19:03:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fdas-application-of-statutory-factors-in-determining-when-a-rems-is-necessary/ 2026-08-05T19:03:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluation-of-sex-specific-data-in-medical-device-clinical-studies-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:03:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessment-of-pressor-effects-of-drugs-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:03:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-immunogenicity-considerations-for-biosimilar-and-interchangeable-insulin-products/ 2026-08-05T19:03:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-of-local-anesthetic-drug-products-with-prolonged-duration-of-effect/ 2026-08-05T19:03:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-investigational-and-licensed-covid-19-convalescent-plasma-guidance-for-industry/ 2026-08-05T19:03:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-180-day-exclusivity-questions-and-answers/ 2026-08-05T19:03:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transmission-of-hepatitis-c-virus-hcv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:03:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/elemental-impurities-in-drug-products-guidance-for-industry/ 2026-08-05T19:03:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/computer-crossmatch-computerized-analysis-of-the-compatibility-between-the-donors-cell-type-and-the-recipients-serum-or-plasma-type-guidance-for-industry/ 2026-08-05T19:03:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-compliance-with-providing-an-acceptable-unique-facility-identifier-for-the-foreign-supplier-verification-programs-for-food-importers-regulation/ 2026-08-05T19:03:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3c-appendix-4/ 2026-08-05T19:03:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compounded-drug-products-that-are-essentially-copies-of-approved-drug-products-under-section-503b-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:03:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/non-inferiority-clinical-trials/ 2026-08-05T19:03:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/toxicity-grading-scale-for-healthy-adult-and-adolescent-volunteers-enrolled-in-preventive-vaccine-clinical-trials-guidance-for-industry/ 2026-08-05T19:03:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/expansion-cohorts-use-in-first-in-human-clinical-trials-to-expedite-development-of-oncology-drugs-and-biologics-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:03:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-of-locally-applied-corticosteroid-products-for-the-short-term-treatment-of-symptoms-associated-with-internal-or-external-hemorrhoids-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:03:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-west-nile-virus-from-donors-of-whole-blood-and-blood-components-intended-for-transfusion-guidance-for-industry/ 2026-08-05T19:03:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/marketing-status-notifications-under-section-506i-of-the-federal-food-drug-and-cosmetic-act/ 2026-08-05T19:03:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/quality-attribute-considerations-for-chewable-tablets-guidance-for-industry/ 2026-08-05T19:03:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-from-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-guidance-for-industry/ 2026-08-05T19:03:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-242-in-use-stability-studies-and-associated-labeling-statements-for-multiple-dose-injectable-animal-drug-products/ 2026-08-05T19:04:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s1b-testing-for-carcinogenicity-of-pharmaceuticals/ 2026-08-05T19:04:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/radiation-biodosimetry-medical-countermeasure-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/testing-of-retroviral-vector-based-human-gene-therapy-products-for-replication-competent-retrovirus-during-product-manufacture-and-patient-follow-up-guidance-for-industry/ 2026-08-05T19:04:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/generally-accepted-scientific-knowledge-in-applications-for-drug-and-biological-products-nonclinical-information/ 2026-08-05T19:04:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/animal-models-essential-elements-to-address-efficacy-under-the-animal-rule_09/ 2026-08-05T19:04:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological-products/ 2026-08-05T19:04:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biological-indicator-bi-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/collecting-and-providing-702b-portions-of-fda-official-samples-draft-guidance-for-industry/ 2026-08-05T19:04:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/complicated-urinary-tract-infections-developing-drugs-for-treatment/ 2026-08-05T19:04:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-the-preparation-of-a-premarket-notification-application-for-a-surgical-mesh-guidance-for-industry-and-or-for-fda-reviewers-staff-and-or-compliance/ 2026-08-05T19:04:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/transition-plan-for-medical-devices-issued-emergency-use-authorizations-euas-related-to-coronavirus-disease-2019-covid-19-guidance-for-industry-other-stakeholders-and-food-and-drug-administrati/ 2026-08-05T19:04:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-265-use-of-data-from-foreign-investigational-studies-to-support-effectiveness-of-new-animal-drugs/ 2026-08-05T19:04:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/ind-submissions-for-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural-recommendations-guidance-for-sponsor-investigators-draft-guidance-for-sponsor-investigators/ 2026-08-05T19:04:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/how-to-obtain-a-covered-product-authorization/ 2026-08-05T19:04:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/product-development-under-the-animal-rule/ 2026-08-05T19:04:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-annex-5-disintegration-test-general-chapter/ 2026-08-05T19:04:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-whole-slide-imaging-in-nonclinical-toxicology-studies-questions-and-answers-guidance-for-industry/ 2026-08-05T19:04:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m10-bioanalytical-method-validation-and-study-sample-analysis/ 2026-08-05T19:04:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/purpose-and-content-of-use-related-risk-analyses-for-drugs-biological-products-and-combination-products/ 2026-08-05T19:04:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q14-analytical-procedure-development/ 2026-08-05T19:04:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cuffless-non-invasive-blood-pressure-measuring-devices-clinical-performance-testing-and-evaluation-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-221-recommendations-for-preparation-and-submission-of-animal-food-additive-petitions/ 2026-08-05T19:04:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cover-letter-attachments-for-controlled-correspondences-and-anda-submissions-guidance-for-industry/ 2026-08-05T19:04:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/exemption-and-exclusion-from-certain-requirements-of-the-drug-supply-chain-security-act-for-the-distribution-of-fda-approved-naloxone-products-during-the-opioid-public-health-emergency-guidance-for-in/ 2026-08-05T19:04:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s3a-guidance-note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies-focus-on-microsampling/ 2026-08-05T19:04:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers/ 2026-08-05T19:04:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-49-evaluating-target-animal-safety-and-effectiveness-of-antibacterial-new-animal-drugs-for-bovine-mastitis/ 2026-08-05T19:04:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/eosinophilic-esophagitis-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:04:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/source-animal-product-preclinical-and-clinical-issues-concerning-the-use-of-xenotransplantation-products-in-humans-guidance-for-industry/ 2026-08-05T19:04:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-100-250-food-facility-registration-human-and-animal-food/ 2026-08-05T19:04:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-delivery-systems-for-andas-draft-guidance-for-industry/ 2026-08-05T19:04:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/technical-considerations-for-non-clinical-assessment-of-medical-devices-containing-nitinol-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/content-and-format-for-abbreviated-510ks-for-early-growth-response-1-egr1-gene-fluorescence-in-situ-hybridization-fish-test-system-for-specimen-characterization-devices-guidance-for-industry-an/ 2026-08-05T19:04:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-73-vich-gl3r-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products/ 2026-08-05T19:04:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-the-design-and-conduct-of-externally-controlled-trials-for-drug-and-biological-products/ 2026-08-05T19:04:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/humanitarian-use-device-hud-designations-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-11-capillary-electrophoresis-general-chapter/ 2026-08-05T19:04:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/developing-medical-imaging-drug-and-biological-products-part-2-clinical-indications/ 2026-08-05T19:04:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/format-and-content-of-a-rems-document-guidance-for-industry/ 2026-08-05T19:04:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/coronary-peripheral-and-neurovascular-guidewires-performance-tests-and-recommended-labeling-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postapproval-pregnancy-safety-studies/ 2026-08-05T19:04:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommended-warning-for-over-the-counter-acetaminophen-containing-drug-products-and-labeling-statements-regarding-serious-skin-reactions/ 2026-08-05T19:04:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/assessing-covid-19-related-symptoms-in-outpatient-adult-and-adolescent-subjects-in-clinical-trials-of-drugs-and-biological-products-for-covid-19-prevention-or-treatment-guidance-for-industry/ 2026-08-05T19:04:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs-for-treatment/ 2026-08-05T19:04:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/statistical-guidance-on-reporting-results-from-studies-evaluating-diagnostic-tests-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:21+00:00 https://www.avancebio.com/cvm-gfi-111-vich-gl19-effectiveness-of-anthelmintics-specific-recommendations-for-canines/ 2026-08-05T19:04:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-otc-human-drug-products-small-entity-compliance-guide-guidance-for-industry/ 2026-08-05T19:04:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e2cr2-periodic-benefit-risk-evaluation-report-pbrer/ 2026-08-05T19:04:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/new-chemical-entity-exclusivity-determinations-for-certain-fixed-combination-drug-products/ 2026-08-05T19:04:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/implementing-a-collection-program-for-source-plasma-containing-disease-associated-and-other-immunoglobulin-igg-antibodies-guidance-for-industry/ 2026-08-05T19:04:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/public-notification-of-emerging-postmarket-medical-device-signals-emerging-signals-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-microbial-vectors-used-for-gene-therapy-guidance-for-industry/ 2026-08-05T19:04:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compliance-with-21-cfr-part-1271-150c1-manufacturing-arrangements-guidance-for-industry/ 2026-08-05T19:04:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recognition-and-use-of-a-standard-for-uniform-blood-and-blood-component-container-labels-guidance-for-industry/ 2026-08-05T19:04:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/process-to-request-a-review-of-fdas-decision-not-to-issue-certain-export-certificates-for-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acne-vulgaris-establishing-effectiveness-of-drugs-intended-for-treatment/ 2026-08-05T19:04:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/extended-release-oral-dosage-forms-development-evaluation-and-application-of-in-vitro-in-vivo-correlations/ 2026-08-05T19:04:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-292-chemistry-manufacturing-and-controls-considerations-for-type-a-medicated-articles/ 2026-08-05T19:04:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-lot-release-protocol-submissions-to-the-center-for-biologics-evaluation-and-research-cber-in-electronic-format-guidance-for-industry/ 2026-08-05T19:04:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transfusion-transmitted-malaria-draft-guidance-for-industry/ 2026-08-05T19:04:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/useful-written-consumer-medication-information-cmi/ 2026-08-05T19:04:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/benefit-risk-considerations-for-product-quality-assessments/ 2026-08-05T19:04:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-for-inclusion-of-pediatric-patients/ 2026-08-05T19:04:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/helicobacter-pylori-associated-duodenal-ulcer-disease-in-adults-developing-drugs-for-treatment/ 2026-08-05T19:04:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/myelodysplastic-syndromes-developing-drug-and-biological-products-for-treatment-draft-guidance-for-industry/ 2026-08-05T19:04:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drugs-for-the-treatment-of-partial-onset-seizures-extrapolation-of-efficacy-from-adults-to-pediatric-patients-1-month-of-age-and-older/ 2026-08-05T19:04:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-for-biosimilar-products-guidance-for-industry/ 2026-08-05T19:04:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/meta-analyses-of-randomized-controlled-clinical-trials-to-evaluate-the-safety-of-human-drugs-or-biological-products/ 2026-08-05T19:04:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e7-studies-in-support-of-special-populations-geriatrics-questions-and-answers/ 2026-08-05T19:04:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-98-dioxin-in-anti-caking-agents-in-animal-feed-and-feed-ingredients/ 2026-08-05T19:04:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postmarketing-studies-and-clinical-trials-implementation-of-section-505o3-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:04:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information-guidance-for-industry/ 2026-08-05T19:04:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q3c-impurities-residual-solvents_2011/ 2026-08-05T19:04:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/facility-readiness-goal-date-decisions-under-gdufa/ 2026-08-05T19:04:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-255-elemental-impurities-in-animal-drug-products-questions-and-answers/ 2026-08-05T19:04:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/patient-matched-guides-for-orthopedic-implants-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonproprietary-naming-of-biological-products-update-guidance-for-industry/ 2026-08-05T19:04:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-and-reviewing-complete-responses-to-clinical-holds-revised/ 2026-08-05T19:04:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/blood-lancet-labeling-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/ndas-impurities-in-drug-substances/ 2026-08-05T19:04:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-screening-testing-and-management-of-blood-donors-and-blood-and-blood-components-based-on-screening-tests-for-syphilis-guidance-for-industry/ 2026-08-05T19:04:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/coordinated-development-of-antimicrobial-drugs-and-antimicrobial-susceptibility-test-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/unique-device-identification-direct-marking-of-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/applying-human-factors-and-usability-engineering-to-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/policy-for-testing-of-alcohol-ethanol-and-isopropyl-alcohol-for-methanol-guidance-for-industry/ 2026-08-05T19:04:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals/ 2026-08-05T19:04:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-for-use-of-histopathology-and-its-associated-methodologies-to-support-biomarker-qualification-guidance-for-industry/ 2026-08-05T19:04:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/enhanced-drug-distribution-security-at-the-package-level-under-the-drug-supply-chain-security-act-guidance-for-industry/ 2026-08-05T19:04:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dosage-and-administration-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/ 2026-08-05T19:04:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/latex-condoms-for-men-information-for-510k-premarket-notifications-use-of-consensus-standards-for-abbreviated-submissions-guidance-for-industry/ 2026-08-05T19:04:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome-assessments/ 2026-08-05T19:04:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-293-fda-enforcement-policy-for-aafco-defined-animal-feed-ingredients/ 2026-08-05T19:04:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cancer-clinical-trial-eligibility-criteria-brain-metastases/ 2026-08-05T19:04:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/certification-process-for-designated-medical-gases-draft-guidance-for-industry/ 2026-08-05T19:04:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/accelerated-approval-and-considerations-for-determining-whether-a-confirmatory-trial-is-underway/ 2026-08-05T19:04:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-142-vich-gl29-pharmacovigilance-of-veterinary-medicinal-products-management-of-periodic-summary-update-reports-psus/ 2026-08-05T19:04:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/wholesale-distributor-verification-requirement-for-saleable-returned-drug-product-and-dispenser-verification-requirements-when-investigating-a-suspect-or-illegitimate-product-compliance-polici-2/ 2026-08-05T19:04:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e7-studies-in-support-of-special-populations-geriatrics/ 2026-08-05T19:04:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment/ 2026-08-05T19:04:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-gastroesophageal-reflux-disease-developing-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:04:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/considerations-in-demonstrating-interchangeability-with-a-reference-product-update/ 2026-08-05T19:04:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/extending-expiration-dates-of-doxycycline-tablets-and-capsules-in-strategic-stockpiles-guidance-for-government-public-health-and-emergency-response-stakeholders/ 2026-08-05T19:04:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/testicular-toxicity-evaluation-during-drug-development/ 2026-08-05T19:04:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects-guidance-for-industry/ 2026-08-05T19:04:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/intravascular-catheters-wires-and-delivery-systems-with-lubricious-coatings-labeling-considerations-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:04:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/label-comprehension-studies-for-nonprescription-drug-products/ 2026-08-05T19:04:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-possible-risk-of-transmission-of-creutzfeldt-jakob-disease-and-variant-creutzfeldt-jakob-disease-by-blood-and-blood-components-guidance-for-industry/ 2026-08-05T19:04:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/proposed-approach-to-regulation-of-cellular-and-tissue-based-products/ 2026-08-05T19:04:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/digital-health-technologies-for-remote-data-acquisition-in-clinical-investigations/ 2026-08-05T19:04:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming-microorganisms-guidance-for-industry/ 2026-08-05T19:04:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/prescription-drug-marketing-act-pdma-requirements-questions-and-answers/ 2026-08-05T19:04:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-68-small-entities-compliance-guide-for-protein-blenders-feed-manufacturers-and-distributors/ 2026-08-05T19:04:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/specifications-for-preparing-and-submitting-electronic-icsrs-and-icsr-attachments/ 2026-08-05T19:04:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-guidance-for-industry/ 2026-08-05T19:04:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transmission-of-human-immunodeficiency-virus-hiv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:04:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-224-supplement-to-vich-gl52-supplemental-examples-for-illustrating-statistical-concepts-described-in-the-vich-in-vivo-bioequivalence-guidance-gl52/ 2026-08-05T19:04:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/wholesale-distributor-verification-requirement-for-saleable-returned-drug-product-compliance-policy-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:04:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dscsa-implementation-product-tracing-requirements-compliance-policy/ 2026-08-05T19:04:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e3-structure-and-content-of-clinical-study-reports/ 2026-08-05T19:04:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-testing-orthopedic-implants-with-modified-metallic-surfaces-apposing-bone-or-bone-cement/ 2026-08-05T19:04:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/supac-mr-modified-release-solid-oral-dosage-forms-scale-up-and-postapproval-changes-chemistry-manufacturing-and-controls-in-vitro-dissolution-testing-and-in-vivo-bioequivalence-documentation-gui/ 2026-08-05T19:04:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/forms-fda-3542a-and-fda-3542-questions-and-answers/ 2026-08-05T19:04:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/impact-resistant-lenses-questions-and-answers-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/how-to-complete-the-vaccine-adverse-event-reporting-system-form-vaers-1-guidance-for-industry/ 2026-08-05T19:04:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/release-of-ora-laboratory-analytical-results-to-the-responsible-party-guidance-for-food-and-drug-administration-staff/ 2026-08-05T19:04:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/determining-donor-eligibility-for-autologous-donors-of-blood-and-blood-components-intended-solely-for-autologous-use-compliance-policy-guidance-for-industry/ 2026-08-05T19:04:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/non-clinical-engineering-tests-and-recommended-labeling-for-intravascular-stents-and-associated-delivery-systems-guidance-for-industry-and-fda-staff/ 2026-08-05T19:04:58+00:00 https://www.avancebio.com/botanical-drug-development-guidance-for-industry/ 2026-08-05T19:04:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/the-use-of-mechanical-calibration-of-dissolution-apparatus-1-and-2-current-good-manufacturing-practice-cgmp-guidance-for-industry/ 2026-08-05T19:04:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/mpox-development-of-drugs-and-biological-products-guidance-for-industry/ 2026-08-05T19:05:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m3r2-nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-authorization-for-pharmaceuticals/ 2026-08-05T19:05:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/reformulating-drug-products-that-contain-carbomers-manufactured-with-benzene/ 2026-08-05T19:05:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/rems-document-technical-conformance-guide/ 2026-08-05T19:05:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-144-vich-gl27-pre-approval-information-for-registration-of-new-veterinary-medicinal-products-for-food-producing-animals-with-respect-to-antimicrobial-resistance/ 2026-08-05T19:05:01+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/psychedelic-drugs-considerations-for-clinical-investigations/ 2026-08-05T19:05:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/revising-anda-labeling-following-revision-of-the-rld-labeling-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:05:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-submission-of-ind-safety-reports-technical-conformance-guide-guidance-for-industry/ 2026-08-05T19:05:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-259-vich-gl58-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products-in-climatic-zones-iii-and-iv/ 2026-08-05T19:05:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-serological-tests-to-reduce-the-risk-of-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii-htlv-i-ii-guidance-for-industry/ 2026-08-05T19:05:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/standards-for-securing-the-drug-supply-chain-standardized-numerical-identification-for-prescription-drug-packages-guidance-for-industry/ 2026-08-05T19:05:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-bayesian-methodology-in-clinical-trials-of-drug-and-biological-products-draft-guidance-for-industry/ 2026-08-05T19:05:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/quality-systems-approach-to-pharmaceutical-current-good-manufacturing-practice-regulations/ 2026-08-05T19:05:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/small-entity-compliance-guide-what-you-need-to-know-about-establishment-and-maintenance-of-records/ 2026-08-05T19:05:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-master-files-for-bulk-antibiotic-drug-substances-guidance-for-industry/ 2026-08-05T19:05:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/master-protocols-for-drug-and-biological-product-development/ 2026-08-05T19:05:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submission-and-review-of-sterility-information-in-premarket-notification-510k-submissions-for-devices-labeled-as-sterile-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cellular-therapy-for-cardiac-disease-guidance-for-industry/ 2026-08-05T19:05:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-recognition-of-acceptable-unique-facility-identifier-ufi-for-the-foreign-supplier-verification-programs-regulation/ 2026-08-05T19:05:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/variations-in-drug-products-that-may-be-included-in-a-single-anda/ 2026-08-05T19:05:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/requirements-for-transactions-with-first-responders-under-section-582-of-the-federal-food-drug-and-cosmetic-act-compliance-policy-guidance-for-industry/ 2026-08-05T19:05:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-89-vich-gl6-eias-for-veterinary-medicinal-products-phase-i/ 2026-08-05T19:05:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing-submission-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-of-anti-infective-drug-products-for-the-pediatric-population-guidance-for-industry/ 2026-08-05T19:05:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/exploratory-ind-studies-guidance-for-industry-investigators-and-reviewers/ 2026-08-05T19:05:10+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/principles-for-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-for-use-in-medical-device-evaluation-guidance-for-industry-and-food-and-drug-administration-staff-a/ 2026-08-05T19:05:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/review-criteria-for-premarket-approval-of-in-vitro-diagnostic-devices-for-detection-of-antibodies-to-parvovirus-b19/ 2026-08-05T19:05:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/regulation-of-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-small-entity-compliance-guide-guidance-for-industry/ 2026-08-05T19:05:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/crohns-disease-developing-drugs-for-treatment/ 2026-08-05T19:05:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/contents-of-a-complete-submission-for-threshold-analyses-and-human-factors-submissions-to-drug-and-biologic-applications/ 2026-08-05T19:05:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-and-licensure-of-vaccines-to-prevent-covid-19-guidance-for-industry/ 2026-08-05T19:05:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/formal-meetings-between-the-food-and-drug-administration-and-sponsors-or-requestors-of-over-the-counter-monograph-drugs/ 2026-08-05T19:05:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-gene-therapy-for-neurodegenerative-diseases-guidance-for-industry/ 2026-08-05T19:05:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarket-notification-510k-submissions-for-bipolar-electrosurgical-vessel-sealers-for-general-surgery-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-169-drug-substance-chemistry-manufacturing-and-controls-information/ 2026-08-05T19:05:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-clarification-on-food-establishment-waiver-from-requirements-of-the-sanitary-transportation-of-human-and-animal-food-rule/ 2026-08-05T19:05:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-72-gmps-for-medicated-feed-manufacturers-not-required-to-register-and-be-licensed-with-fda/ 2026-08-05T19:05:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions/ 2026-08-05T19:05:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acceptance-review-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-product-communications-that-are-consistent-with-the-fda-required-labeling-questions-and-answers-guidance-for-industry/ 2026-08-05T19:05:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acceptance-of-clinical-data-to-support-medical-device-applications-and-submissions-frequently-asked-questions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-281-infectious-otitis-externa-drugs-for-topical-use-in-dogs/ 2026-08-05T19:05:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/policy-for-coronavirus-disease-2019-tests-revised-guidance-for-developers-and-food-and-drug-administration-staff/ 2026-08-05T19:05:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postmarketing-safety-reporting-for-human-drug-and-biological-products-including-vaccines-draft-guidance-for-industry/ 2026-08-05T19:05:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chemotherapy-induced-nausea-and-vomiting-developing-drugs-for-prevention-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:05:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/procedures-for-class-ii-device-exemptions-from-premarket-notification-guidance-for-industry-and-cdrh-staff/ 2026-08-05T19:05:19+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/inclusion-of-older-adults-in-cancer-clinical-trials-guidance-for-industry/ 2026-08-05T19:05:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/regulatory-classification-of-pharmaceutical-co-crystals/ 2026-08-05T19:05:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-219-vich-gl51-statistical-evaluation-of-stability-data/ 2026-08-05T19:05:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pharmacogenomic-data-submissions/ 2026-08-05T19:05:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-considerations-for-investigational-device-exemptions-ides-for-neurological-devices-targeting-disease-progression-and-clinical-outcomes-guidance-for-industry-and-food-and-drug-administratio/ 2026-08-05T19:05:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-268-adaptive-and-other-innovative-designs-for-effectiveness-studies-of-new-animal-drugs/ 2026-08-05T19:05:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/utilizing-animal-studies-to-evaluate-organ-preservation-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/integration-of-dose-counting-mechanisms-into-mdi-drug-products/ 2026-08-05T19:05:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biocompatibility-testing-of-medical-devices-standards-specific-information-for-the-accreditation-scheme-for-conformity-assessment-asca-program-draft-guidance-for-industry-accreditation-bodies/ 2026-08-05T19:05:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-liquids-and-or-soft-foods-as-vehicles-for-drug-administration-general-considerations-for-selection-and-in-vitro-methods-for-product-quality-assessments/ 2026-08-05T19:05:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-document-for-the-preparation-of-ides-for-spinal-systems-guidance-for-industry-and-or-fda-staff/ 2026-08-05T19:05:24+00:00 https://www.avancebio.com/cvm-gfi-108-registering-with-cvms-electronic-submission-system/ 2026-08-05T19:05:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s2r1-genotoxicity-testing-and-data-interpretation-for-pharmaceuticals-intended-for-human-use/ 2026-08-05T19:05:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q1e-evaluation-of-stability-data/ 2026-08-05T19:05:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/fda-and-industry-actions-on-premarket-approval-applications-pmas-effect-on-fda-review-clock-and-goals-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-92-vich-gl10r-impurities-in-new-veterinary-drug-substances/ 2026-08-05T19:05:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-110-vich-gl16-effectiveness-of-anthelmintics-specific-recommendations-for-porcines/ 2026-08-05T19:05:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/standardized-format-for-electronic-submission-of-nda-and-bla-content-for-the-planning-of-bioresearch-monitoring-bimo-inspections-for-cder-submissions-guidance-for-industry/ 2026-08-05T19:05:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-electronic-and-non-electronic-format-promotional-labeling-and-advertising-materials-for-human-prescription-drugs/ 2026-08-05T19:05:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/laser-products-conformance-with-iec-60825-1-ed-3-and-iec-60601-2-22-ed-3-1-laser-notice-no-56-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:28+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions/ 2026-08-05T19:05:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/definitions-of-suspect-product-and-illegitimate-product-for-verification-obligations-under-the-drug-supply-chain-security-act-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:05:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/shelf-life-of-medical-devices/ 2026-08-05T19:05:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/mitigating-the-risk-of-cross-contamination-from-valves-and-accessories-used-for-irrigation-through-flexible-gastrointestinal-endoscopes-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dscsa-implementation-product-tracing-requirements-for-dispensers-compliance-policy-revised-guidance-for-industry/ 2026-08-05T19:05:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/drug-and-device-manufacturer-communications-with-payors-formulary-committees-and-similar-entities-questions-and-answers-draft-guidance-for-industry/ 2026-08-05T19:05:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-submission-of-expedited-safety-reports-from-ind-exempt-ba-be-studies-guidance-for-industry/ 2026-08-05T19:05:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/controlled-correspondence-related-to-generic-drug-development/ 2026-08-05T19:05:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/annual-status-report-information-and-other-submissions-for-postmarketing-requirements-and-commitments-using-forms-fda-3988-and-fda-3989-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:05:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/providing-regulatory-submissions-in-alternate-electronic-format-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:05:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/supac-ss-nonsterile-semisolid-dosage-forms-scale-up-and-post-approval-changes-chemistry-manufacturing-and-controls-in-vitro-release-testing-and-in-vivo-bioequivalence-documentation-guidance-for/ 2026-08-05T19:05:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/anda-submissions-prior-approval-supplements-under-gdufa-guidance-for-industry/ 2026-08-05T19:05:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biological-product-deviation-reporting-for-licensed-manufacturers-of-biological-products-other-than-blood-and-blood-components/ 2026-08-05T19:05:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medical-device-reporting-for-user-facilities/ 2026-08-05T19:05:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-91-vich-gl8-r-stability-testing-for-medicated-premix-or-type-a-medicated-article-revision-1/ 2026-08-05T19:05:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/policy-for-monkeypox-tests-to-address-the-public-health-emergency-guidance-for-laboratories-commercial-manufacturers-and-food-and-drug-administration-staff/ 2026-08-05T19:05:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/select-updates-for-non-clinical-engineering-tests-and-recommended-labeling-for-intravascular-stents-and-associated-delivery-systems-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q13-continuous-manufacturing-of-drug-substances-and-drug-products-guidance-for-industry/ 2026-08-05T19:05:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals-supply-chain-program/ 2026-08-05T19:05:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/contact-dermatitis-from-topical-drug-products-for-cutaneous-application-human-safety-assessment-guidance-for-industry/ 2026-08-05T19:05:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/diagnostic-ecg-guidance-including-non-alarming-st-segment-measurement-guidance-for-industry/ 2026-08-05T19:05:39+00:00 https://www.avancebio.com/general-wellness-policy-for-low-risk-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/mammography-quality-standards-act-and-regulation-amendments-small-entity-compliance-guide-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/electronic-submission-template-for-medical-device-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hospital-and-health-system-compounding-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:05:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e17-general-principles-for-planning-and-design-of-multi-regional-clinical-trials/ 2026-08-05T19:05:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-284-using-relative-supersaturation-to-support-urinary-tract-health-claims-for-adult-maintenance-cat-food/ 2026-08-05T19:05:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/best-practices-in-developing-proprietary-names-for-human-prescription-drug-products-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:05:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-218-cell-based-products-for-animal-use/ 2026-08-05T19:05:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigational-ivds-used-in-clinical-investigations-of-therapeutic-products-draft-guidance-for-industry-food-and-drug-administration-staff-sponsors-and-institutional-review-boards/ 2026-08-05T19:05:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/responding-to-unsolicited-requests-for-off-label-information-about-prescription-drugs-and-medical-devices/ 2026-08-05T19:05:45+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/menstrual-products-performance-testing-and-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/surgical-sutures-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pdes-for-triethylamine-and-for-methylisobutylketone/ 2026-08-05T19:05:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/anthrax-developing-drugs-for-prophylaxis-of-inhalational-anthrax-guidance-for-industry/ 2026-08-05T19:05:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-158-use-of-material-from-deer-and-elk-in-animal-feed/ 2026-08-05T19:05:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-225-vich-gl53-electronic-exchange-of-documents-file-format-recommendations/ 2026-08-05T19:05:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/marketing-submission-recommendations-for-a-predetermined-change-control-plan-for-artificial-intelligence-enabled-device-software-functions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-238-modified-release-veterinary-parenteral-dosage-forms-development-evaluation-and-establishment-of-specifications/ 2026-08-05T19:05:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bundling-multiple-devices-or-multiple-indications-in-a-single-submission-guidance-for-industry-and-fda-staff/ 2026-08-05T19:05:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chemistry-manufacturing-and-controls-flexibilities-for-developing-human-cellular-and-gene-therapy-products-for-a-biologics-license-application-guidance-for-industry/ 2026-08-05T19:05:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/ecopy-program-for-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-to-reduce-the-risk-of-transmission-of-disease-agents-associated-with-sepsis-by-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-draft-guidance-for-industry/ 2026-08-05T19:05:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-study-datasets-for-vaccines-to-the-office-of-vaccines-research-and-review-guidance-for-industry-technical-specifications-document/ 2026-08-05T19:05:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-resorbable-adhesion-barrier-devices-for-use-in-abdominal-and-or-pelvic-surgery-guidance-for-industry/ 2026-08-05T19:05:50+00:00 https://www.avancebio.com/guidance-for-the-preparation-of-a-premarket-notification-for-extended-laparoscopy-devices-eld/ 2026-08-05T19:05:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:05:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/compounded-drug-products-that-are-essentially-copies-of-a-commercially-available-drug-product-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/ 2026-08-05T19:05:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/internet-social-media-platforms-with-character-space-limitations-presenting-risk-and-benefit-information-for-prescription-drugs-and-medical-devices/ 2026-08-05T19:05:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/center-for-devices-and-radiological-health-cdrh-appeals-processes-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/uncomplicated-gonorrhea-developing-drugs-for-treatment/ 2026-08-05T19:05:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/180-day-exclusivity-when-multiple-andas-are-submitted-on-the-same-day/ 2026-08-05T19:05:54+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/adaptive-designs-for-medical-device-clinical-studies-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/individual-product-bioequivalence-recommendations-for-specific-products/ 2026-08-05T19:05:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-regulatory-requirements-for-medical-devices-fda-89-4203/ 2026-08-05T19:05:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/withdrawn-cder-product-specific-guidances/ 2026-08-05T19:05:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-information-for-x-ray-imaging-device-premarket-notifications-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/anda-submissions-refuse-to-receive-standards-questions-and-answers-guidance-for-industry/ 2026-08-05T19:05:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/potency-assay-considerations-for-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral-pathogens/ 2026-08-05T19:05:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submitting-separate-marketing-applications-and-clinical-data-for-purposes-of-assessing-user-fees-guidance-for-industry/ 2026-08-05T19:05:57+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clarification-of-radiation-control-regulations-for-manufacturers-of-diagnostic-x-ray-equipment-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:05:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/use-of-donor-screening-tests-to-test-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-for-infection-with-treponema-pallidum-syphilis-guidance-for-industry/ 2026-08-05T19:05:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/premarketing-risk-assessment-guidance-for-industry/ 2026-08-05T19:05:58+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fee-waivers-for-fdc-and-co-packaged-hiv-drugs-for-pepfar/ 2026-08-05T19:05:59+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-or-detection-and-differentiation-of-human-papillomaviruses-guidance-for-industry-and-food-and-drug-admini/ 2026-08-05T19:06:00+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-235-current-good-manufacturing-practice-requirements-for-food-for-animals/ 2026-08-05T19:06:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/brief-summary-and-adequate-directions-for-use-disclosing-risk-information-in-consumer-directed-print-advertisements-and-promotional-labeling-for-prescription-drugs/ 2026-08-05T19:06:02+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-276-effectiveness-of-anthelmintics-specific-recommendations-for-products-proposed-for-the-prevention-of-heartworm-disease-in-dogs/ 2026-08-05T19:06:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e14-and-s7b-clinical-and-nonclinical-evaluation-of-qt-qtc-interval-prolongation-and-proarrhythmic-potential-questions-and-answers-guidance-for-industry/ 2026-08-05T19:06:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/review-criteria-for-assessment-of-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and-cardiac-c-reactive-assays-guidance-for-industry-and-fda-staff/ 2026-08-05T19:06:03+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-187b-heritable-intentional-genomic-alterations-in-animals-the-approval-process/ 2026-08-05T19:06:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q1c-stability-testing-for-new-dosage-forms/ 2026-08-05T19:06:04+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers/ 2026-08-05T19:06:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q2r1-validation-of-analytical-procedures-text-and-methodology-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:06:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s10-photosafety-evaluation-of-pharmaceuticals/ 2026-08-05T19:06:05+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-63-vich-gl1-validation-of-analytical-procedures-definition-and-terminology/ 2026-08-05T19:06:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-study-designs-for-surgical-ablation-devices-for-treatment-of-atrial-fibrillation-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:06+00:00 https://www.avancebio.com/cvm-gfi-166-vich-gl38-environmental-impact-assessments-eias-for-veterinary-medicinal-products-vmps-phase-ii/ 2026-08-05T19:06:06+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m4qr2-the-common-technical-document-for-the-registration-of-pharmaceuticals-for-human-use-quality/ 2026-08-05T19:06:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-considerations-to-mitigate-the-risks-of-misconnections-with-small-bore-connectors-intended-for-enteral-applications-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:07+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submission-of-premarket-notifications-for-magnetic-resonance-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/opioid-use-disorder-endpoints-for-demonstrating-effectiveness-of-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:06:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/general-principles-for-evaluating-the-abuse-deterrence-of-generic-solid-oral-opioid-drug-products-guidance-for-industry/ 2026-08-05T19:06:08+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ 2026-08-05T19:06:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/interpretation-of-the-deemed-to-be-a-license-provision-of-the-biologics-price-competition-and-innovation-act-of-2009-guidance-for-industry/ 2026-08-05T19:06:09+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/geriatric-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:06:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/investigational-enzyme-replacement-therapy-products-nonclinical-assessment-guidance-for-industry/ 2026-08-05T19:06:11+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/requests-for-reconsideration-at-the-division-level-under-gdufa/ 2026-08-05T19:06:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postmarket-surveillance-under-section-522-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/submission-of-quality-metrics-data-guidance-for-industry/ 2026-08-05T19:06:12+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/intent-to-exempt-certain-unclassified-medical-devices-from-premarket-notification-requirements-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-279-demonstrating-bioequivalence-for-type-a-medicated-articles-containing-active-pharmaceutical-ingredients-considered-to-be-poorly-soluble-in-aqueous-media-that-exhibit-little-to-no-syste/ 2026-08-05T19:06:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cancer-clinical-trial-eligibility-criteria-laboratory-values-draft-guidance-for-industry-irbs-and-clinical-investigators/ 2026-08-05T19:06:13+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/safety-testing-of-human-allogeneic-cells-expanded-for-use-in-cell-based-medical-products/ 2026-08-05T19:06:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/notifying-fda-of-a-discontinuance-or-interruption-in-manufacturing-of-finished-products-or-active-pharmaceutical-ingredients-under-section-506c-of-the-fdc-act/ 2026-08-05T19:06:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e14-clinical-evaluation-of-qt-qtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs/ 2026-08-05T19:06:14+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/diabetic-foot-infections-developing-drugs-for-treatment/ 2026-08-05T19:06:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/current-good-manufacturing-practice-guidance-for-human-drug-compounding-outsourcing-facilities-under-section-503b-of-the-fdc-act-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:06:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-143-vich-gl30-pharmacovigilance-of-veterinary-medicinal-products-controlled-list-of-terms/ 2026-08-05T19:06:15+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-80-evaluation-the-utility-of-anti-salmonella-chemical-food-additives/ 2026-08-05T19:06:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dissolution-testing-of-immediate-release-solid-oral-dosage-forms/ 2026-08-05T19:06:16+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description-information-for-a-biological-in-vitro-diagnostic-product-guidance-for-industry/ 2026-08-05T19:06:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/third-party-review-guidance-for-phacofragmentation-system-device-premarket-notification-510k/ 2026-08-05T19:06:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e2a-clinical-safety-data-management-definitions-and-standards-for-expedited-reporting/ 2026-08-05T19:06:17+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chronic-fatigue-syndrome-myalgic-encephalomyelitis-developing-drug-products-for-treatment/ 2026-08-05T19:06:18+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-gene-therapy-products-incorporating-human-genome-editing-guidance-for-industry/ 2026-08-05T19:06:20+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-114-vich-gl21-effectiveness-of-anthelmintics-specific-recommendations-for-chickens-gallus-gallus/ 2026-08-05T19:06:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/quality-management-system-information-for-certain-premarket-submission-reviews-draft-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/early-clinical-trials-with-live-biotherapeutic-products-chemistry-manufacturing-and-control-information-guidance-for-industry/ 2026-08-05T19:06:21+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/homeopathic-drug-products-guidance-for-fda-staff-and-industry/ 2026-08-05T19:06:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/the-use-of-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-for-oral-drug-product-development-manufacturing-changes-and-controls-draft-guidance-for-industry/ 2026-08-05T19:06:22+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-pdufa-products/ 2026-08-05T19:06:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/q1d-bracketing-and-matrixing-designs-for-stability-testing-of-new-drug-substances-and-products/ 2026-08-05T19:06:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/plasma-derived-from-therapeutic-plasma-exchange/ 2026-08-05T19:06:23+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s5r3-detection-of-reproductive-and-developmental-toxicity-for-human-pharmaceuticals-guidance-for-industry/ 2026-08-05T19:06:24+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pediatric-rare-diseases-a-collaborative-approach-for-drug-development-using-gaucher-disease-as-a-model-draft-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:06:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/time-and-extent-applications-for-nonprescription-drug-products/ 2026-08-05T19:06:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-hospitals-nursing-homes-and-other-health-care-facilities-fda-public-health-advisory-guidance-for-hospitals-nursing-homes-and-other-health-care-facilities/ 2026-08-05T19:06:25+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-207-vich-gl48-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-marker-residue-depletion-studies-to-establish-product-withdrawal-periods/ 2026-08-05T19:06:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/design-considerations-for-pivotal-clinical-investigations-for-medical-devices-guidance-for-industry-clinical-investigators-institutional-review-boards-and-fda-staff/ 2026-08-05T19:06:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/dosage-delivery-devices-for-orally-ingested-otc-liquid-drug-products/ 2026-08-05T19:06:26+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/user-fees-and-refunds-for-premarket-notification-submissions-510ks-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-178-recommended-design-and-evaluation-of-effectiveness-studies-for-swine-respiratory-disease-claims/ 2026-08-05T19:06:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/responsibilities-of-laser-light-show-projector-manufacturers-dealers-and-distributors-laser-notice-51/ 2026-08-05T19:06:27+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/air-powered-dental-handpieces-and-air-motors-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pregnant-women-scientific-and-ethical-considerations-for-inclusion-in-clinical-trials/ 2026-08-05T19:06:29+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-evaluation-of-endocrine-related-drug-toxicity/ 2026-08-05T19:06:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e11-clinical-investigation-of-medicinal-products-in-the-pediatric-population/ 2026-08-05T19:06:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/alternate-source-of-the-active-pharmaceutical-ingredient-in-pending-andas-guidance-for-industry/ 2026-08-05T19:06:30+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/human-gene-therapy-for-retinal-disorders-guidance-for-industry/ 2026-08-05T19:06:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-on-informed-consent-for-in-vitro-diagnostic-device-studies-using-leftover-human-specimens-that-are-not-individually-identifiable-guidance-for-sponsors-institutional-review-boards-and-food/ 2026-08-05T19:06:31+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cancer-clinical-trial-eligibility-criteria-patients-with-hiv-hepatitis-b-virus-or-hepatitis-c-virus-infections/ 2026-08-05T19:06:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/medication-guides-distribution-requirements-and-inclusion-in-risk-evaluation-and-mitigation-strategies-rems/ 2026-08-05T19:06:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/labeling-otc-human-drug-products-questions-and-answers/ 2026-08-05T19:06:32+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-for-treatment-guidance-for-industry/ 2026-08-05T19:06:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pet-drug-products-current-good-manufacturing-practice-cgmp/ 2026-08-05T19:06:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cpg-sec-335-800-clinical-thermometer-adulteration-misbranding-defects/ 2026-08-05T19:06:33+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/obesity-and-overweight-developing-drugs-and-biological-products-for-weight-reduction/ 2026-08-05T19:06:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/acceptance-and-filing-reviews-for-premarket-approval-applications-pmas-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/reports-on-the-status-of-postmarketing-study-commitments-implementation-of-section-130-of-the-food-and-drug-administration-modernization-act-of-1997/ 2026-08-05T19:06:34+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/physicochemical-and-structural-q3-characterization-of-topical-drug-products-submitted-in-andas/ 2026-08-05T19:06:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-240-proprietary-names-for-new-animal-drugs/ 2026-08-05T19:06:35+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/early-collaboration-meetings-under-the-fda-modernization-act-fdama-final-guidance-for-industry-and-for-cdrh-staff/ 2026-08-05T19:06:35+00:00 https://www.avancebio.com/reporting-drug-sample-information-under-section-6004-of-the-affordable-care-act/ 2026-08-05T19:06:36+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/antibacterial-therapies-for-patients-with-an-unmet-medical-need-for-the-treatment-of-serious-bacterial-diseases/ 2026-08-05T19:06:37+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/draft-guidance-for-industry-supplemental-questions-and-answers-regarding-food-facility-registration/ 2026-08-05T19:06:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hcv-resistance-data-attachment-to-guidance/ 2026-08-05T19:06:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/irritable-bowel-syndrome-clinical-evaluation-of-products-for-treatment/ 2026-08-05T19:06:38+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biosimilarity-and-interchangeability-additional-draft-qas-on-biosimilar-development-and-the-bpci-act-revision-1-draft-guidance-for-industry/ 2026-08-05T19:06:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/evaluation-of-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers/ 2026-08-05T19:06:39+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/development-of-a-shared-system-rems-guidance-for-industry/ 2026-08-05T19:06:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-testing-for-salmonella-species-in-human-foods-and-direct-human-contact-animal-foods/ 2026-08-05T19:06:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/current-good-tissue-practice-cgtp-and-additional-requirements-for-manufacturers-of-human-cells-tissues-and-cellular-and-tissue-based-products-hct-ps-guidance-for-industry/ 2026-08-05T19:06:40+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/container-closure-system-and-component-changes-glass-vials-and-stoppers/ 2026-08-05T19:06:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/pregnancy-lactation-and-reproductive-potential-labeling-for-human-prescription-drug-and-biological-products-content-and-format-draft-guidance-for-industry/ 2026-08-05T19:06:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biological-product-deviation-reporting-for-blood-and-plasma-establishments-guidance-for-industry/ 2026-08-05T19:06:41+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/child-resistant-packaging-statements-in-drug-product-labeling-guidance-for-industry/ 2026-08-05T19:06:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/hypertension-conducting-studies-of-drugs-to-treat-patients-on-a-background-of-multiple-antihypertensive-drugs-guidance-for-industry/ 2026-08-05T19:06:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-104-content-and-format-of-effectiveness-and-target-animal-safety-technical-sections-and-final-study-reports-for-submission/ 2026-08-05T19:06:42+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/annual-reportable-labeling-changes-for-new-drug-applications-and-abbreviated-new-drug-applications-for-nonprescription-drug-products/ 2026-08-05T19:06:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-foreign-supplier-verification-programs-for-importers-of-food-for-humans-and-animals/ 2026-08-05T19:06:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/changes-to-an-approved-application-biological-products-human-blood-and-blood-components-intended-for-transfusion-or-for-further-manufacture-final-guidance/ 2026-08-05T19:06:43+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/s11-nonclinical-safety-testing-in-support-of-development-of-pediatric-pharmaceuticals-international-council-for-harmonisation-draft-guidance-for-industry/ 2026-08-05T19:06:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/e18-genomic-sampling-and-management-of-genomic-data-guidance-for-industry/ 2026-08-05T19:06:44+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/biosimilars-and-interchangeable-biosimilars-licensure-for-fewer-than-all-conditions-of-use-for-which-the-reference-product-has-been-licensed-guidance-for-industry-draft-guidance-for-industry/ 2026-08-05T19:06:46+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/nonclinical-safety-assessment-of-oligonucleotide-based-therapeutics/ 2026-08-05T19:06:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-review-staff-and-industry-good-review-management-principles-and-practices-for-pdufa-products/ 2026-08-05T19:06:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/efficacy-studies-to-support-marketing-of-fibrin-sealant-products-manufactured-for-commercial-use-guidance-for-industry/ 2026-08-05T19:06:47+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/replacing-color-additives-in-approved-or-marketed-drug-products-draft-guidance-for-industry/ 2026-08-05T19:06:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-and-food-and-drug-administration-staff-assemblers-guide-to-diagnostic-x-ray-equipment/ 2026-08-05T19:06:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/guidance-for-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls/ 2026-08-05T19:06:48+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/policy-for-evaluating-impact-of-viral-mutations-on-covid-19-tests-revised-guidance-for-test-developers-and-food-and-drug-administration-staff/ 2026-08-05T19:06:49+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/leveraging-prior-knowledge-in-the-development-of-human-gene-therapy-products-incorporating-genome-editing/ 2026-08-05T19:06:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/optimizing-the-dosage-of-human-prescription-drugs-and-biological-products-for-the-treatment-of-oncologic-diseases-guidance-for-industry-availability/ 2026-08-05T19:06:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/volume-limits-for-automated-collection-of-source-plasma/ 2026-08-05T19:06:50+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/in-vitro-companion-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/ 2026-08-05T19:06:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-data-needed-to-support-the-licensure-of-pandemic-influenza-vaccines-guidance-for-industry/ 2026-08-05T19:06:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/streamlining-the-donor-interview-process-recommendations-for-self-administered-questionnaires-guidance-for-industry/ 2026-08-05T19:06:51+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/postoperative-nausea-and-vomiting-developing-drugs-for-prevention/ 2026-08-05T19:06:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/availability-of-fdas-esubmitter-program-for-regulatory-submissions-from-licensed-blood-establishments-guidance-for-industry/ 2026-08-05T19:06:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/m4-the-ctd-quality-questions-and-answers-location-issues/ 2026-08-05T19:06:52+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-290-vich-gl61-pharmaceutical-development/ 2026-08-05T19:06:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/bacterial-risk-control-strategies-for-blood-collection-establishments-and-transfusion-services-to-enhance-the-safety-and-availability-of-platelets-for-transfusion-guidance-for-industry/ 2026-08-05T19:06:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/recommendations-for-blood-establishments-training-of-back-up-personnel-assessment-of-blood-donor-suitability-and-reporting-certain-changes-to-an-approved-application-guidance-for-industry/ 2026-08-05T19:06:53+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/questions-and-answers-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmaceuticals-to-limit-potential-carcinogenic-risk-guidance-for-industry/ 2026-08-05T19:06:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-254-donor-eligibility-for-animal-cells-tissues-and-cell-and-tissue-based-products/ 2026-08-05T19:06:55+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/cvm-gfi-120-veterinary-feed-directive-regulation-questions-and-answers/ 2026-08-05T19:06:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png https://www.avancebio.com/clinical-trial-imaging-endpoint-process-standards-guidance-for-industry/ 2026-08-05T19:06:56+00:00 https://www.avancebio.com/wp-content/uploads/2018/06/pdf.png